Document:

YM
      BIOSCIENCES INC.

    AMENDED
      AND RESTATED STOCK OPTION PLAN

    (amended
      November 28, 2007)

     

    1.  PURPOSE
      OF THE PLAN

    

    The
      purpose of the Plan is to attract, retain and motivate persons of training,
      experience and leadership as key service providers to the Corporation and its
      Subsidiaries, including their directors, officers and employees, and to advance
      the interests of the Corporation by providing such persons with the opportunity,
      through share options, to acquire an increased proprietary interest in the
      Corporation.

    

    2.  DEFINED
      TERMS

    

    Where
      used herein, the following terms shall have the following meanings,
      respectively:

    

    

    “AIM”
      means
      the Alternative Investment Market of the London Stock Exchange;

    

    “AMEX”
means
      the American Stock and Options Exchange;

    

    “Black-out
      Period”
means
      the period during which the Corporation has imposed trading restrictions on
      its
      Insiders and certain other persons pursuant to its insider trading and
      disclosure policies;

    

    “Board”
      means
      the Board of Directors of the Corporation or, if established and duly authorized
      to act, the Executive Committee of the Board of Directors of the
      Corporation;

    

    “Committee”
shall
      have the meaning attributed thereto in Section 3.1 hereof;

    

    “Corporation”
      means YM
      Biosciences Inc. and includes any successor corporation thereof;

    

    “Eligible
      Person”
      Means:

    

    
      	 	
              (i)

            	
              any
                Insider, director, officer or employee of the Corporation or any
                Subsidiary, or any other Service Provider (an “Eligible
                Individual”);
                or

            

    

     

    
      	 	
              (ii)

            	
              a
                corporation controlled by an Eligible Individual, the issued and
                outstanding voting shares of which are, and will continue to be,
                beneficially owned, directly or indirectly, by such Eligible Individual
                and/or the spouse, children and/or grandchildren of such Eligible
                Individual (an “Employee
                Corporation”);

            

    

    

    “Insider”
      means
      any insider, as such term is defined in Subsection 1(1) of the Securities
      Act
      (Ontario), of the Corporation, other than a person who falls within that
      definition solely by virtue of being a director or senior officer of a
      Subsidiary, and includes any associate, as such term is defined in Subsection
      1(1) of the Securities
      Act
      (Ontario), of any such insider;

     

    “Market
      Place” at
      any
      date in respect of the Shares means the closing sale price of such Shares on
      the
      TSX (or, if such Shares are not then listed and posted for trading on the TSX,
      then on the AMEX, or if such Shares are not so listed on the AMEX, then on
      the
      AIM, or if such Shares are not so listed on the AIM, then on the recognized
      stock exchange on which such Shares are listed on which the greatest volume
      of
      them were traded during the period referenced below or, if such Shares are
      not
      so listed on any recognized stock exchange, then on the over-the-counter market
      on which they are traded as selected for such purpose by the Committee) on
      the
      trading day immediately preceding such date. In the event that such Shares
      did
      not trade on such trading day, the Market Place shall be the average of the
      bid
      and ask prices in respect of such Shares at the close of trading on such trading
      day;

    

    “Option”
      means
      an
      option to purchase Shares granted to an Eligible Person under the
      Plan;

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    “Option
      Price”
      means
      the price per Share at which Shares may be purchased under an Option, as the
      same may be adjusted from time to time in accordance with Article 8
      hereof;

    

    “Optioned
      Shares”
      means
      the Shares issuable pursuant to an exercise of Options;

    

    “Optionee”
      means
      an
      Eligible Person to whom an Option has been granted and who continues to hold
      such Option;

    

    “Plan”
      means
      this Amended and Restated Stock Option Plan, as the same may be further amended
      or varied from time to time;

    

    “Service
      Provider” means
      any
      person or company engaged as an independent contractor or otherwise to provide
      ongoing management or consulting services for the Corporation or for any entity
      controlled by the Corporation;

    

    “Shares”
      means
      the Common Shares of the Corporation or, in the event of an adjustment
      contemplated by Article 8 hereof, such other shares or securities to which
      an
      Optionee may be entitled upon the exercise of an Option as a result of such
      adjustment; 

    

    “Subsidiary”
      means
      any corporation which is a subsidiary, as such term is defined in Subsection
      1(2) of the Business
      Corporations Act
      (Ontario), of the Corporation; and

    

    “TSX”
      means
      the
      Toronto Stock Exchange.

    

    3.  ADMINISTRATION
      OF THE PLAN

    

    The
      Plan
      shall be administered by the compensation committee (the “Committee”)
      of the
      Board.

    

    The
      Committee shall have the power, where consistent with the general purpose and
      intent of the Plan and subject to the specific provisions of the
      Plan:

    

    
      	 	
              (a)

            	
              to
                establish policies and to adopt rules and regulations for carrying
                out the
                purposes, provisions and administration of the
                Plan;

            

    

     

    
      	 	
              (b)

            	
              to
                interpret and construe the Plan and to determine all questions arising
                out
                of the Plan or any Option, and any such interpretation, construction
                or
                determination made by the Committee shall be final, binding and conclusive
                for all purposes;

            

    

    

    
      	 	
              (c)

            	
              to
                determine the number of Shares covered by each
                Option;

            

    

    

    
      	 	
              (d)

            	
              to
                determine the Option Price of each
                Option;

            

    

    

    
      	 	
              (e)

            	
              to
                determine the time or times when Options will be granted and
                exercisable;

            

    

    

    
      	 	
              (f)

            	
              to
                determine if the Shares which are issuable on the exercise of an
                Option
                will be subject to any restrictions upon the exercise of such Option;
                and

            

    

    

    
      	 	
              (g)

            	
              to
                prescribe the form of the instruments relating to the grant, exercise
                and
                other terms of Options.

            

    

    

    Subject
      as hereinafter provided in this Section 3.3, no member of the Committee shall,
      during the currency of his or her membership on the Committee, be entitled
      to
      participate in the Plan. A member of the Committee may be entitled to
      participate in the Plan only if an Option is granted, and the terms and
      provisions thereof determined, by the Board without such member of the Committee
      participating in any many whatsoever in the granting of an Option to, or the
      determinations made with respect to, such member of the Committee or to such
      Option; and the Board shall, with respect to such member of the Committee,
      be
      vested with all power and authority otherwise granted to the Committee pursuant
      to the Plan and the term “Committee” as used herein shall mean the Board for
      such purposes.

    
      
        
        

      

      
        -
          2
          -

        
          

        

      

      
        
        

      

    

     

    The
      Committee may, in its discretion, require as conditions to the grant or exercise
      of any Option that the Optionee shall have:

    

    
      	 	
              (a)

            	
              represented,
                warranted and agreed in form and substance satisfactory to the Corporation
                that he or she is acquiring and will acquire such Option and the
                Shares to
                be issued upon the exercise thereof or, as the case may be, is acquiring
                such Shares, for his or her own account, for investment and not with
                a
                view to or in connection with any distribution, that he or she has
                had
                access to such information as is necessary to enable him or her to
                evaluate the merits and risks of such investment and that he or she
                is
                able to bear the economic risk of holding such Shares for an indefinite
                period;

            

    

     

    
      	 	
              (b)

            	
              agreed
                to restrictions on transfer in form and substance satisfactory to
                the
                Corporation and to an endorsement on any option agreement on certificate
                representing the Shares making appropriate reference to such restrictions;
                and

            

    

    

    
      	 	
              (c)

            	
              agreed
                to indemnify the Corporation in connection with the
                foregoing.

            

    

    

    Any
      Option granted under the Plan shall be subject to the requirement that, if
      at
      any time counsel to the Corporation shall determine that the listing,
      registration or qualification of the Shares subject to such Option upon any
      securities exchange or under any law or regulation of any jurisdiction, or
      the
      consent or approval of any securities exchange or any governmental or regulatory
      body, is necessary as a condition of, or in connection with, the grant or
      exercise of such Option or the issuance or purchase of Shares thereunder, such
      Option may not be accepted or exercised in whole or in part unless such listing,
      registration, qualification, consent or approval shall have been effected or
      obtained on conditions acceptable to the Committee. Nothing herein shall be
      deemed to require the Corporation to apply for or to obtain such listing,
      registration, qualification, consent or approval.

    

    4. SHARES
      SUBJECT TO THE PLAN

    

    Subject
      to adjustment as provided in Article 8 hereof, the Shares to be offered under
      the Plan shall consist of the Corporation’s authorized but unissued common
      shares. The aggregate number of Shares issuable upon the exercise of all options
      granted under the Plan shall not exceed 15% of the issued and outstanding shares
      of the Corporation as at the date of grant of each Option under the Plan. If
      any
      Option granted hereunder shall expire or terminate for any reason in accordance
      with the terms of the Plan without being exercised, the un-purchased shares
      subject thereto shall again be available for the purpose of this
      Plan.

    

    5. ELIGIBILITY;
      GRANT; TERMS OF OPTIONS

     

    Options
      may be granted to any Eligible Person in accordance with Section 5.2
      hereof.

     

    Options
      may be granted by the Corporation pursuant to the recommendations of the
      Committee from time to time provided and to the extent that such decisions
      are
      approved by the Board.

    

    Subject
      as herein and otherwise specifically provided in this Article 5, the number
      of
      Shares subject to each Option, the Option Price of each Option, the expiration
      date of each Option, the extent to which each Option is exercisable from time
      to
      time during the term of the Option and other terms and conditions relating
      to
      each such Option shall be determined by the Committee.

    

    Notwithstanding
      the expiration date applicable to any Option, if an Option would otherwise
      expire during or immediately after a Black-out Period, then the expiration
      date
      of such Option shall be the tenth business day following the expiration of
      the
      Black-out Period, provided that in no event shall the period during which said
      Option is exercisable be extended beyond 10 years from the date such Option
      is
      granted to the Optionee. 

    

    In
      the
      event that no specific determination is made by the Committee with respect
      to
      any of the following matters, each Option shall, subject to any other specific
      provisions of the Plan, contain the following terms and
      conditions:

    
      
        
        

      

      
        -
          3
          -

        
          

        

      

      
        
        

      

    

    
      	 	
              (a)

            	
              the
                period during which an Option shall be exercisable shall be 10 years
                from
                the date the Option is granted to the Optionee; and
                

            

    

     

    
      	 	
              (b)

            	
              the
                Optionee may exercise the Option for not more than 20% of the Shares
                covered by the Option during each 12 month period following the first
                anniversary of the date of the grant of the Option; provided, however,
                that if the number of Shares purchased pursuant to exercises of the
                Option
                during any such 12 month period is less than 20% of the Shares covered
                by
                the Option, the Optionee shall have the right, at any time or from
                time to
                time during the remainder of the term of the Option, to purchase
                such
                number of Shares subject to the Option which were purchasable, but
                not
                purchased by him or her, during such 12 month
                period.

            

    

    

    Subject
      to any adjustments pursuant to the provisions of Article 8 hereof, the Option
      Price of any Option shall be in no circumstances be lower than the Market Price
      on the date of which the grant of the Option is approved by the Committee.
      Notwithstanding the foregoing, in the event that the Shares are not listed
      on
      any stock exchange on the date on which the grant of an Option is approved
      by
      the Committee, the Option Price for such Option shall be determined by the
      Committee. If, as and when any Shares have been duly purchased and paid for
      under the terms of an Option, such Shares shall be conclusively deemed allotted
      and issued as fully paid non-assessable Shares at the price paid
      therefor.

     

    No
      Options shall be granted to any Optionee if the total number of Shares issuable
      to such Optionee under this Plan, together with any Shares reserved for issuance
      to such Optionee under options for services or any other stock option plans,
      would exceed 5% of the issued and outstanding Shares.

    

    An
      Option
      is personal to the Optionee and non-assignable (whether by operation of law
      or
      otherwise), except as provided for herein. Upon any attempt to transfer, assign,
      pledge, hypothecate or otherwise dispose of an Option contrary to the provisions
      of the Plan, or upon the levy of any attachment or similar process upon an
      Option, the Option shall, at the election of the Corporation, cease and
      terminate and be of no further force or effect whatsoever.

    

    No
      Options shall be granted to an Optionee if such grant could result, at any
      time,
      in:

    

    
      	 	
              (a)

            	
              the
                number of Shares reserved for issuance pursuant to Options or other
                stock
                options granted to Insiders exceeding 10% of the issued and outstanding
                Shares; 

            

    

     

    
      	 	
              (b)

            	
              the
                issuance to Insiders, within a one-year period, of a number of Shares
                exceeding 10% of the issued and outstanding Shares;
                or

            

    

    

    
      	 	
              (c)

            	
              the
                issuance to any one Insider and such Insider’s associates, within a
                one-year period, of a number of Shares exceeding 5% of the issued
                and
                outstanding Shares.

            

    

    

    For
      the
      purposes of this Section 5.8, the phrase “issued and outstanding Shares”
excludes any Shares issued pursuant to the Plan or other stock options, stock
      option plans, employee stock purchase plans or other compensation or incentive
      mechanisms, over a preceding one-year period and “associate” means any person
      associated with such Insider.

    

    6. TERMINATION
      OF EMPLOYMENT; DEATH

    

    Subject
      to Sections 6.2 and 6.3 hereof and to any express resolution passed by the
      committee with respect to an Option, an Option and all rights to purchase Shares
      pursuant thereto shall expire and terminate immediately upon the Optionee who
      holds such Option ceasing to be an Eligible Person. 

    

    If,
      before the expiry of an Option in accordance with the terms thereof, an Optionee
      shall cease to be an Eligible Person (an “Event
      of Termination”)
      for any
      reason other than his or her resignation or the termination for “cause” of his
      or her employment with the Corporation or any Subsidiary, or his or her
      resignation or failure to be re-elected as a director of the Corporation or
      any
      Subsidiary, then the Optionee may:

    
      
        
        

      

      
        -
          4
          -

        
          

        

      

      
        
        

      

    

    
      	 	
              (a)

            	
              exercise
                the Option to the extent that he or she was entitled to do so at
                the time
                of such Event of Termination, at any time up to and including, but
                not
                after, a date that is three (3) months (or such other longer period
                as may
                be determined by the Board in its sole discretion) following the
                date of
                such Event of Termination, or prior to the close of business on the
                expiration date of the Option, whichever is earlier;
                and

            

    

     

    
      	 	
              (b)

            	
              with
                the prior written consent of the Board or the Committee, which consent
                may
                be withheld in the Corporation’s sole discretion, exercise a further
                Option at any time up to and including, but not after, a date that
                is
                three (3) months (or such other longer period as may be determined
                by the
                Board in its sole discretion) following the date of such Event of
                Termination, or prior to the close of business on the expiration
                date of
                the Option, whichever is earlier, to purchase all or any of the Optioned
                Shares as the Board or the Committee may designate but not exceeding
                the
      number of Optioned Shares the Optionee would have otherwise
                been entitled
                to purchase pursuant to the Option had the Optionee’s status as an
                Eligible Person been maintained for the term of the
                Option.

            

    

    

    If
      an
      Optionee dies before the expiry of an Option in accordance with the terms
      thereof, the Optionee’s legal representative(s) may, subject to the terms of the
      Option and the Plan:

    

    
      	 	
              (a)

            	
              exercise
                the Option to the extent that the Optionee was entitled to do so
                at the
                date of his or her death at any time up to and including, but not
                after, a
                date one year following the date of death of the Optionee, or prior
                to the
                close of business on the expiration date of the Option, whichever
                is
                earlier; and

            

    

     

    
      	 	
              (b)

            	
              with
                the prior written consent of the Board or the Committee, exercise
                at any
                time up to and including, but not after, a date one year following
                the
                date of death of the Optionee, a further Option to purchase all or
                any of
                the Optioned Shares as the Board or the Committee may designate but
                not
                exceeding the number of Optioned Shares the Optionee would have otherwise
                been entitled to purchase had the Optionee
                survived.

            

    

    

    For
      greater certainty, Options shall not be affected by any change of employment
      of
      the Optionee or by the Optionee ceasing to be a director of the Corporation
      provided that the Optionee continues to be an Eligible Person.

     

    For
      the
      purposes of this Article 6, a determination by the Corporation that an Optionee
      was discharged for “cause” shall be binding on the Optionee; provided, however,
      that such determination shall not be conclusive of the Optionee’s potential
      entitlement to damages for the loss of the right to exercise an Option in the
      event that a court of competent jurisdiction ultimately determines that the
      discharge was without “cause”.

    

    If
      the
      Optionee is an Employee Corporation, the references to the Optionee in this
      Article 6 shall be deemed to refer to the Eligible Individual associated with
      the Employee Corporation.

    

    7. EXERCISE
      OF OPTIONS

    

    Subject
      to the provisions of the Plan, an Option may be exercised from time to time
      by
      delivery to the Corporation at its registered office of a written notice of
      exercise addressed to the Secretary of the Corporation specifying the number
      of
      Shares with respect to which the Option is being exercised and, subject to
      Section 6881350
      hereof,
      accompanied by payment in full, by cash or cheque, of the Option Price of the
      Shares then being purchased. Certificates for such Shares shall be issued and
      delivered to the Optionee within a reasonable time following the receipt of
      such
      notice and payment.

     

    Notwithstanding
      any of the provisions contained in the Plan or in any Option, the Corporation’s
      obligation to issue Shares to an Optionee pursuant to the exercise of any Option
      shall be subject to:

    

    
      	 	
              (a)

            	
              completion
                of such registration or other qualification of such Shares or obtaining
                approval of such governmental or regulatory authority as the Corporation
                shall determine to be necessary or advisable in connection with the
                authorization, issuance or sale
                thereof;

            

    

     

    
      	 	
              (b)

            	
              the
                administration of such Shares to listing on any stock exchange on
                which
                the Shares may then be listed;

            

    

     

    
      
        
        

      

      
        -
          5
          -

        
          

        

      

      
        
        

      

    

    
      	 	
              (c)

            	
              the
                receipt from the Optionee of such representations, warranties, agreements
                and undertakings, as the Corporation determines to be necessary or
                advisable in order to safeguard against the violation of the securities
                laws of any jurisdiction; and

            

    

    

    
      	 	
              (d)

            	
              the
                satisfaction of any conditions on exercise prescribed pursuant to
                Section
                3.4 hereof.

            

    

    

    In
      this
      connection the Corporation shall, to the extent necessary, take all commercially
      reasonable steps to obtain such approvals, registrations, and qualifications
      as
      may be necessary for the issuance of such Shares in compliance with applicable
      securities laws and for the listing of such Shares on any stock exchange on
      which the Share are then listed.

    

    Options
      shall be evidenced by a share option agreement, instrument or certificate in
      such form not inconsistent with this Plan as the Committee may from time to
      time
      determine as provided for under Subsection 3.2(g), provided that the substance
      of Article 5 be included therein.

    

    Any
      Optionee may elect to effect a cashless exercise of any or all of such
      Optionee’s right under an option. In connection with any such cashless exercise,
      the Optionee shall be entitled to receive, without any cash payment (other
      than
      the taxes required to be paid in connection with the exercise which must be
      paid
      by the Optionee to the Corporation in cash at the time of exercise), such number
      of whole common shares (rounded down to the nearest whole number) obtained
      pursuant to the following formula: 

    

    
      	 	
              x
                

            	
              =
                

            	
              [a
                (b – c)]

            
	 	 	 	
              b

            
	
              where

            	 	 	 
	 	 	 	 
	 	
              x

            	
              =

            	
              the
                number of whole common shares to be issued

            
	 	 	 	 
	 	
              a

            	
              =

            	
              the
                number of common shares under option

            
	 	 	 	 
	 	
              b

            	
              =

            	
              the
                market price of the common shares as at the last trading immediately
                prior
                to the cashless exercise

            
	 	 	 	 
	 	
              c

            	
              =

            	
              the
                exercise price of the option

            

    

    

    In
      connection with any such cashless exercise, the full number of common shares
      issuable (item (a) in the formula) shall be considered to have been issued
      for
      the purposes of the reduction in the number of common shares which may be issued
      under the Plan.

    

    8. CERTAIN
      ADJUSTMENTS

    

    In
      the
      event of any subdivision or redivision of the Shares into a greater number
      of
      Shares at any time after the grant of an Option to any Optionee and prior to
      the
      expiration of the term of such Option, the Corporation shall deliver to such
      Optionee at the time of any subsequent exercise of his or her Option in
      accordance with the terms hereof, in lieu of the number of shares to which
      he or
      she was theretofore entitled upon such exercise, but for the same aggregate
      consideration payable therefor, such number of Shares as such Optionee would
      have held as a result of such subdivision or redivision if, on the record date
      thereof, the Optionee had been the registered holder of the number of Shares
      to
      which he or she was theretofore entitled upon such exercise.

     

    In
      the
      event of any consolidation of the Shares into a lesser number of Shares at
      any
      time after the grant of an Option to any Optionee and prior to the expiration
      of
      the term of such Option, the Corporation shall deliver to such Optionee at
      the
      time of any subsequent exercise of his or her Option in accordance with the
      terms hereof, in lieu of the number of Shares to which he or she was theretofore
      entitled upon such exercise, but for the same aggregate consideration payable
      therefor, such number of Shares as such Optionee would have held as a result
      of
      such consolidation if, on the record date thereof, the Optionee had been the
      registered holder of the number of Shares to which he or she was theretofore
      entitled upon such exercise.

    
      
        
        

      

      
        -
          6
          -

        
          

        

      

      
        
        

      

    

    Subject
      to the provisions of Article 9, if at any time after the grant of any Option
      to
      an Optionee and prior to the expiration of the term of such Option, the Shares
      shall be reclassified, reorganized or otherwise changed, otherwise than as
      specified in Sections 8.1 and 8.2 or the Corporation shall consolidate, merge
      or
      amalgamate with or into another corporation (the corporation resulting or
      continuing from such consolidation, merger or amalgamation being herein called
      the “Successor
      Corporation”)
      or, the
      Corporation shall pay a stock dividend (other than any dividends in the ordinary
      course), the Optionee shall be entitled to receive upon the subsequent exercise
      of his or her Option in accordance with the terms hereof and shall accept in
      lieu of the number of Shares to which he or she was theretofore entitled upon
      such exercise but for the same aggregate consideration payable therefor, the
      aggregate the number of shares of the appropriate class and/or other securities
      of the Corporation or the Successor Corporation (as the case may be) that the
      Optionee would have been entitled to receive as a result of such
      reclassification, reorganization or other change or as a result of such
      consolidation, merger, amalgamation, or stock dividend, if on the record date
      of
      such reclassification, reorganization, other change or stock dividend, or the
      record date of such consolidation, merger or amalgamation or dividend payment,
      as the case may be, he or she had been the registered holder of the number
      of
      Shares to which he or she was theretofore entitled upon such
      exercise.

     

    In
      the
      event the Corporation should declare and pay a special cash dividend or other
      distribution out of the ordinary course, a special dividend in specie on the
      Shares, or a stock dividend other than in the ordinary course, the Option Price
      of all Options outstanding on the record date of such dividend or other
      distribution shall be reduced by an amount equal to the cash payment or other
      distribution or the fair market value of the dividend in specie or stock
      dividend or other distribution, as determined by the Committee in its sole
      discretion.

    

    9.   AMENDMENT
      OR DISCONTINUANCE OF THE PLAN

    

    Subject
      to applicable regulatory requirements and except as provided herein, the Board
      may, in its sole and absolute discretion and without shareholder approval,
      amend, suspend, terminate or discontinue the Plan and may amend the terms and
      conditions of Options granted pursuant to the Plan. Provided, however, that
      if
      the Board wishes to increase the maximum percentage in Section 4.1 hereof or
      extend the Option period or reduce the Option Price of Options granted to
      Insiders of the Corporation pursuant to the Plan, shareholder approval will
      be
      required.

     

    Without
      limiting the generality of the foregoing, the Board may make the following
      amendments to the Plan, without obtaining shareholder approval:

    

    
      	 	
              (a)

            	
              amendments
                to the terms and conditions of the Plan necessary to ensure that
                the Plan
                complies with the applicable regulatory requirements, including the
                rules
                of the TSX, in place from time to
                time;

            

    

    

    
      	 	
              (b)

            	
              amendments
                to the provisions of the Plan respecting administration of the Plan
                and
                eligibility for participation under the
                Plan;

            

    

    

    
      	 	
              (c)

            	
              amendments
                to the provisions of the Plan respecting the terms and conditions
                on which
                options may be granted pursuant to the Plan, including the provisions
                relating to the option price, the option period and the vesting schedule;
                and

            

    

    

    
      	 	
              (d)

            	
              amendments
                to the Plan that are of a “housekeeping”
nature.

            

    

    

    Without
      limiting the generality of the foregoing, the Board may amend the Option Price,
      the option period, the vesting schedule and the termination provisions of
      Options granted pursuant to the Plan, without shareholder approval. Provided,
      however, that. if the Board proposes to reduce the Option Price or extend the
      option period of options granted to Insiders of the Corporation pursuant to
      the
      Plan, such amendments will require shareholder approval.

    

    10. MISCELLANEOUS
      PROVISIONS

    

    An
      Optionee shall not have any rights as a shareholder of the Corporation with
      respect to any of the Shares covered by such Option until the date of issuance
      of a certificate for Shares upon the exercise of such Option, in full or in
      part, and then only with respect to the Shares represented by such certificate
      or certificates. Without in any way limiting the generality of the foregoing,
      no
      adjustment shall be made for dividends or other rights for which the record
      date
      is prior to the date such share certificate is issued.

    
      
        
        

      

      
        -
          7
          -

        
          

        

      

      
        
        

      

    

    Nothing
      in the Plan or any Option shall confer upon an Optionee any right to continue
      or
      be re-elected as a director of the Corporation or any right to continue in
      the
      employ of the Corporation or any Subsidiary, or affect in any way the right
      of
      the Corporation or any Subsidiary to terminate his or her employment at any
      time; nor shall anything in the Plan or any Option be deemed or construed to
      constitute an agreement, or an expression of intent, on the part of the
      Corporation or any Subsidiary to extend the employment of any Optionee beyond
      the time which he or she would be normally be retired pursuant to the provisions
      of any present or future retirement plan of the Corporation or any Subsidiary
      or
      any present or future retirement policy of the Corporation or any Subsidiary,
      or
      beyond the time at which he or she would otherwise be retired pursuant to the
      provisions of any contract of employment with the Corporation or any
      Subsidiary.

    

    Notwithstanding
      Section 5.8 hereof, Options may be transferred or assigned between an Eligible
      Individual and the related Employee Corporation provided the assignor delivers
      notice to the Corporation prior to the assignment.

    

    The
      Plan
      and all matters to which reference is made herein shall be governed by and
      interpreted in accordance with the laws of the Province of Ontario and the
      laws
      of Canada applicable therein.

    

    11. SHAREHOLDER
      AND REGULATORY APPROVAL

    

    11.1 The
      Plan
      shall be subject to ratification by the shareholders of the Corporation to
      be
      effected by a resolution passed at a meeting of the shareholders of the
      Corporation, and to acceptance by the TSX and any other relevant regulatory
      authority. Any Options granted prior to such ratification and acceptance shall
      be conditional upon such ratification and acceptance being given and no such
      Options may be exercised unless and until such ratification and acceptance
      are
      given.

    
      
        
        

      

      
        -
          8
          -(1)
      CIMYM, Inc.

    

    (2)
      CIMAB S.A.

    

    And

    

    (3)
      Oncoscience AG

     

    
      
        

      

       

    

    Amended
      and Restated

    Development
      and Licence Agreement

    Relating
      to TheraCIM h-R3

     

    
      
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Development
      and Licence Agreement

    

    This
      Amended and Restated Development and Licence Agreement
      (this
“Agreement”) dated 15 August 2007 is made between:

    

    
      	(1)	
              CIMYM,
                Inc.
                (company registration number 12142) (“CIMYM”), a company incorporated in
                Barbados, whose principal place of business is at Sagicor Centre,
                Wildey,
                St. Michael, Barbados, West Indies;
                and

            

    

    

    
      	(2)	
              CIMAB
                S.A.
                (company registration number 107/92) (“CIMAB”), a company incorporated in
                Cuba, whose principal place of business is at 206 Street, No. 1926,
                e/ 19
                y 21, Atabey, Playa, Havana City, Cuba;
                and

            

    

    

    
      	(3)	
              Oncoscience
                AG
                (company registration number HRB 5414) (“Oncoscience”) a company
                incorporated in Germany, whose principal place of business is at
                Hafenstraße
                32, 22880
                Wedel, Germany.

            

    

    

    Recitals:

    

    
      	A.	
              The
                Parties entered into a development and licence agreement dated 17
                November
                2003 (the “Original Agreement”).

            

    

    

    
      	B.	
              The
                Parties wish to enter into this Agreement for the purposes of wholly
                replacing and superseding the Original
                Agreement.

            

    

    

    
      	C.	
              CIMYM
                is the exclusive licensee of certain Licensed Patent Rights, certain
                Licensed Know-how (each as defined below) relating to an antibody
                known as
                TheraCIM h-R3 (as defined below).

            

    

    

    
      	D.	
              The
                shareholders of CIMYM are YM Biosciences, Inc. and
                CIMAB.

            

    

    

    
      	E.	
              CIMAB
                enters into commercial agreements on behalf of the Center of Molecular
                Immunology (“CIM”, as defined below). CIM originally developed TheraCIM
                h-R3 and has the facilities to manufacture Licensed Products (as
                defined
                below). CIMAB is entering into this Agreement principally in order
                to
                assume the manufacturing and supply obligations set out in Clause
                5.

            

    

    

    
      	F.	
              Oncoscience
                has expertise in cancer immunotherapy and experience in conducting
                immunotherapy clinical trials in cancer
                patients.

            

    

    

    
      	G.	
              Oncoscience
                wishes to pursue the further development and commercialisation of
                TheraCIM
                h-R3 for the treatment of cancer in humans, in accordance with the
                provisions of this Agreement.

            

    

    

    
      	H.	
              CIMYM
                is willing to grant to Oncoscience, and Oncoscience is willing to
                accept,
                a licence in the Field under the Licensed Patent Rights and to use
                the
                Licensed Know-how, all in accordance with the provisions of this
                Agreement.

            

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    It
      is agreed as follows:

    

    1.
      Definitions

    

    In
      this
      Agreement, the following words shall have the following meanings:

    

    
      	
              Affiliate

            	
               

            	
              In
                relation to CIMYM or Oncoscience, means any entity or person that
                controls, is controlled by, or is under common control with that
                Party.
                For the purposes of this definition, “control” shall mean direct or
                indirect beneficial ownership of 50% (or, outside a Party’s home
                territory, such lesser percentage as is the maximum, permitted level
                of
                foreign investment) or more of the share capital, stock or other
                participating interest carrying the right to vote or to distribution
                of
                profits of that entity or person, as the case may be.

            
	
               

            	
               

            	
               

            
	
              Arising
                Intellectual Property

            	
               

            	
              Any
                and all of the Arising Patents and the Arising
                Know-how.

            
	
               

            	
               

            	
               

            
	
              Arising
                Know-how 

            	
               

            	
              Technical,
                commercial and all other information generated by Oncoscienee or
                its
                Affiliates or sub-licensees during the continuation of this Agreement
                that
                relates to any of the Licensed Intellectual Property or the Licensed
                Product, including any scientific or regulatory data (including clinical
                data), product licence applications and approvals, clinical trial
                licence
                applications and approvals, and development and marketing plans and
                activities.

            
	
               

            	
               

            	
               

            
	
              Arising
                Patents 

            	
               

            	
              Any
                and all patents and patent applications that may be applied for or
                obtained in respect of any invention(s) made by Oncoscience, its
                Affiliates or sub-licensees during the continuation of this Agreement
                and
                which relate to any Licensed Intellectual Property or the Licensed
                Product, together with any continuations, continuations in part,
                extensions, re-issues, divisions, and any patents, supplementary
                protection certificates and similar rights that are based on or derive
                priority from the foregoing.

            
	
               

            	
               

            	
               

            
	
              Calendar
                Quarter 

            	
               

            	
              Each
                three-month period ending on 31st March, 30th June,
                30th September and 3lst December.

            
	
               

            	
               

            	
               

            
	
              Calendar
                Year 

            	
               

            	
              A
                year commencing on lst January and ending on 31st
                December (but commencing on the Commencement Date in the first year
                of
                this Agreement and, in the final year of this Agreement, ending on
                the
                date of the last sale of Licensed Product under this
                Agreement).

            
	
               

            	
               

            	
               

            
	
              CIM
                

            	
               

            	
              The
                Center of Molecular Immunology, a scientific research institute based
                in
                Havana, Cuba.

            
	
               

            	
               

            	
               

            
	
              CIMAB’s
                Contract Manufacturer

            	
               

            	
              Any
                Person that may from time to time be contracted by CIMAB to manufacture
                the Licensed Product, or any component or ingredient thereof, in
                accordance with the provisions of this Agreement.

            
	
               

            	
               

            	
               

            
	
              CIMYM
                Field and Territory

            	
               

            	
              (a)
                outside the Territory, all fields (including the Field); and 

              (b)
                within the Territory, all fields other than the
                Field).

            

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    

    
      	
              Claims
                

            	
               

            	
              All
                demands, claims and liability (whether criminal or civil, in contract,
                tort or otherwise) for losses, damages, legal costs and other expenses
                of
                any nature whatsoever and all costs and expenses (including without
                limitation legal costs) incurred in connection
                therewith.

            
	
               

            	
               

            	
               

            
	
              Co-exclusive
                Licence 

            	
               

            	
              A
                licence whereby:

            
	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (a)

            	
              both
                CIMAB and Oncoscienee may exercise the licensed rights in the field
                and
                territory of the licence in question

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (b)

            	
              Oncoscience
                may grant sub-licences to the extent permitted under Clause 6.4;
                and

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (c)

            	
              CIMAB
                may appoint a single, further licensee from time to time in each
                part of
                such field and territory to exercise such rights in its place,
                but

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (d)

            	
              except
                as described in (c) above CIMAB may not grant further licences in
                such
                field and territory for as long as the co-exclusive licence continues,
                subject to the provisions of this Agreement and the requirements
                of any
                applicable law.

            
	
               

            	
               

            	
               

            	
               

            
	
              Commencement
                Date 

            	
               

            	
              The
                date of execution of this Agreement by the Parties (or, if they sign
                on
                different dates, the last date of signature of this Agreement by
                a
                Party).

            
	
               

            	
               

            	
               

            
	
              Delivered
                Items 

            	
               

            	
              Has
                the meaning given in Clause 4.2.

            
	
               

            	
               

            	
               

            
	
              Development
                and Commercialisation Plan

            	
               

            	
              The
                development and commercialisation plan for Licensed Product to be
                defined
                and agreed in accordance with Clause 3.1, as amended from time to
                time by
                agreement in writing of the Parties. An initial programme of work,
                which
                is anticipated to form the basis of a more detailed Development and
                Commercialisation Plan, is briefly summarised in the attached Schedule
                3.

            
	
               

            	
               

            	
               

            
	
              Development
                and Commercialisation Report

            	
               

            	
              The
                report described in Clause 3.4 as amended from time to
                time.

            
	
               

            	
               

            	
               

            
	
              Development
                Team Parties

            	
               

            	
              CIMYM
                and Oncoscience, and “Development Team Party” shall mean either of
                them.

            
	
               

            	
               

            	
               

            
	
              Development
                Term 

            	
               

            	
              In
                respect of each country in the Territory, means the period from the
                Commencement Date until completion of the development of TheraCIM
                h-R3 to
                the point of first commercial sale of a Licensed Product in that
                country
                in accordance with the Development and Commercialisation
                Plan.

            
	
               

            	
               

            	
               

            
	
              Diligent
                and Reasonable Efforts

            	
               

            	
              Exerting
                such efforts and employing such resources (whether by itself or through
                sub-contractors or sub-licensees) as would normally be exerted or
                employed
                by a reasonable third party pharmaceutical company for a product
                of
                similar market potential at a similar stage of its product life,
                when
                utilizing sound and reasonable scientific, business and medical practice
                and judgment in order to develop the product in a timely manner and
                maximize the economic return to the Parties from its
                commercialisation.

            

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    

    
      	
              Field
                

            	
               

            	
              The
                treatment of cancer in humans.

            
	
               

            	
               

            	
               

            
	
              Gross
                Sales Value 

            	
               

            	
              Any
                and all amounts received (including the value of any non-monetary
                consideration received) for the sale of the Licensed Product by
                Oncoscience or its Affiliates from a third party (including any of
                Oncoscience’s sub-licensees) in an arm’s length transaction exclusively
                for money (or where the sale is not at arm’s length, the price that would
                have been so invoiced and received if it had been at arm’s length), after
                deduction of all documented:

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (a)
                

            	
              normal
                trade discounts actually granted and any credits actually given (including
                for rejected or returned Licensed Product),

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (b)

            	
              rebates
                to customers and third parties,

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (c)

            	
              provided
                the amounts are separately charged on the relevant invoice any costs
                of
                packaging, insurance, carriage and freight,

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (d)

            	
              any
                value added tax or other sales or use tax charged to the
                customer

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (e)

            	
              any
                import or export duties or similar applicable government levies;
                provided
                that such deductions do not exceed reasonable and customary amounts
                in the
                markets in which such sales occurred; 

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              provided
                that in no event the total of deductions referred to in paragraphs
                (a) to
                (e) above will exceed 10% (ten percent) of the total
                invoice. 

            
	 	 	 	 
	
              Initial
                Development Programme

            	 	
              A
                programme of development to be conducted by Oncoscience in accordance
                with
                the provisions of Schedule 3 Part A.

            
	 	 	 
	
              Joint
                Development Team 

            	 	
              A
                committee to be established, and operating, in accordance with the
                provisions of Clause 2.

            
	 	 	 
	
              Know-how
                

            	 	
              The
                Licensed Know-how and the Arising Know-how.

            
	 	 	 
	
              Licensed
                Intellectual Property

            	 	
              Any
                and all of the Licensed Patent Rights and Licensed Know-how.
                

            
	 	 	 
	
              Licensed
                Know-how 

            	 	
              Technical
                information in the possession of CIMYM or CIMAB in the Field relating
                to
                (a) TheraCIM h-R3 and/or (b) the inventions claimed in the Licensed
                Patent
                Rights, and being further described in the attached Schedule 2, in
                each
                case to the extent that such information is relevant to the development
                and commercialisation of the Licensed
                Product.

            

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    

    
      	
              Licensed
                Patent Rights 

            	
               

            	
              The
                patents and patent applications described in the attached Schedule
                1
                subject to the provisions of Schedule 1, together with any continuations,
                continuations in part, extensions, reissues, divisions, and any patents,
                supplementary protection certificates and similar rights that are
                based on
                or derive priority from the foregoing.

            
	
               

            	
               

            	
               

            
	
              Licensed
                Product 

            	
               

            	
              TheraCIM
                h-R3 that is sold or otherwise supplied by Oncoscience or its Affiliate
                or
                sub-licensee and which (a) is within any Valid Claim of the Licensed
                Patent Rights and/or (b) is the subject of any Orphan Drug Status
                in the
                Territory; and/or (c) incorporates, or its development makes use
                of, any
                of the Licensed Know-how.

            
	
               

            	
               

            	
               

            
	
              Major
                Country 

            	
               

            	
              Germany,
                France, Italy, Spain or the United Kingdom.

            
	
               

            	
               

            	
               

            
	
              Milestone
                Receipts 

            	
               

            	
              The
                amount of any payment, excluding Value Added Tax, (other than sales
                income
                on which Oncoscience pays CIMYM a royalty under Clause 7.1 or 7.2,
                including any payments to Oncoscience or its Affiliate for Licensed
                Product supplied directly by Oncoscience or its Affiliate for sale
                or
                promotion by Oncoscience’s Affiliates or sub-licensees) obtained by, or
                due to, Oncoscience or its Affiliate and the value of any non-monetary
                receipt, in relation to the development or sub-licensing (including
                the
                grant of any option over a sub-licence) of any Licensed Intellectual
                Property (“Relevant Transaction”), and including any of the following in
                relation to a Relevant Transaction:

            
	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (a)
                

            	
              up-front,
                licence, milestone (whether at the stage of development, marketing
                or
                otherwise), success, bonus, maintenance and periodic (including annual)
                fees and other payments, and minimum royalty payments (to the extent
                not
                offset against royalties based on sales and coming within the definition
                of Royalty Receipts), due under any sub-licence
                agreement;

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (b)
                

            	
              any
                receipt greater than actual incurred cost in respect of the funding
                of
                research or development activities related to the Licensed Product,
                provided that such incurred costs shall not include any costs that
                were
                incurred prior to the date of the agreement under which such funding
                was
                provided;

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (c)
                

            	
              where
                any sub-licence is to be granted under cross-licensing arrangements,
                the
                value of any third party licence obtained under such
                arrangements;

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (d)
                

            	
              any
                premium paid over the fair market value of shares, options or other
                securities in respect of any of the share capital of Oncoscience
                or its
                Affiliate (such fair market value to be determined on the assumption
                that
                CIMYM had not granted, nor agreed to grant, any rights to Oncoscience
                in
                respect of any Licensed Intellectual Property);

            
	
               

            	
               

            	
               

            	
               

            
	
               

            	
               

            	
              (e)
                

            	
              any
                loan, guarantee or other financial benefit made or given other than
                on
                normal market terms; and

            

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    

    
      	
               

            	
               

            	
              (f)
                

            	
              any
                shares, options or other securities obtained from a third
                party.

            
	
               

            	
               

            	
               

            
	
              Net
                Sales Value

            	
               

            	
              The
                Gross Sales Value after deduction of the Supply Price.

            
	
               

            	
               

            	
               

            
	
              Oncoscience
                Field and Territory

            	
               

            	
              In
                respect of any activity that is licensed to Oncoscience under this
                Agreement, shall mean that the activity must occur both within the
                Field
                and within the Territory.

            
	
               

            	
               

            	
               

            
	
              Orphan
                Drug Status

            	
               

            	
              The
                grant of “orphan designation” by the European Commission for a medicinal
                product pursuant to Regulation (EC) No. 141/2000 of 16 December 1999
                or
                any similar designation in any part of the Territory.

            
	
               

            	
               

            	
               

            
	
              Parties
                

            	
               

            	
              CIMYM,
                CIMAB and Oncoscience, and “Party” shall mean any of
                them.

            
	
               

            	
               

            	
               

            
	
              Person

            	
               

            	
              Includes
                any individual, firm, company, corporation or other legal
                entity.

            
	
               

            	
               

            	
               

            
	
              Patents
                

            	
               

            	
              Any
                and all of the Licensed Patent Rights and the Arising Patents.
                

            
	
               

            	
               

            	
               

            
	
              Payment
                Cap

            	
               

            	
              
                Has
                  the meaning given in Clause 7.1.

              

            
	
               

            	
               

            	
               

            
	
              Providing
                Parties 

            	
               

            	
              Any
                and all of CIMAB (whether on its own behalf or on behalf of CIM)
                and CIMYM
                and Providing Party shall mean either of them.

            
	
               

            	
               

            	
               

            
	
              Regulatory
                Application 

            	
               

            	
              Any
                and all applications that are necessary and appropriate to obtain
                Regulatory Approval including, without limitation, all required documents,
                data and information concerning, filed or required to be filed, otherwise
                submitted by Oncoscience, its Affiliate or licensee to a Regulatory
                Authority.

            
	
               

            	
               

            	
               

            
	
              Regulatory
                Approval 

            	
               

            	
              Any
                and all approvals, licences, registrations or authorisations of any
                Regulatory Authority that are necessary for the manufacture, use,
                storage,
                import, export, transport, marketing, distribution or sale of the
                Licensed
                Product in any part of the Territory.

            
	
               

            	
               

            	
               

            
	
              Regulatory
                Authority 

            	
               

            	
              The
                European Medicines Evaluation Agency and other regulatory authorities
                in
                the Territory.

            
	
               

            	
               

            	
               

            
	
              Supply
                Agreement 

            	
               

            	
              Any
                agreement between CIMAB and Oncoscience under which CIMAB agrees
                to
                manufacture and supply Oncoscience with Licensed
                Product.

            
	
               

            	
               

            	
               

            
	
              Supply
                Price 

            	
               

            	
              The
                commercial supply price for the Licensed Product payable by Oncoscience
                to
                CIMAB in accordance with Clause
                5.2.

            

    

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    

    
      	
              Territory
                

            	
               

            	
              Shall
                mean the following countries and territories: Austria, Belgium, Denmark,
                Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Portugal,
                Spain, Sweden, The Netherlands, United Kingdom, Cyprus, Czech Republic,
                Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia,
                Bulgaria, Romania, Turkey, Albania, Andorra, Belarus, Bosnia-Herzegovina,
                Croatia, Former Yugoslav Republic of Macedonia, Iceland, Liechtenstein,
                Moldova, Monaco, Norway, Russia, San Marino, Serbia and Montenegro,
                Switzerland, Ukraine and Vatican City.

            
	
               

            	
               

            	
               

            
	
              TheraCIM
                h-R3 

            	
               

            	
              A
                humanised antibody to the EGF receptor, known scientifically as h-R3
                and
                which has been given the product name TheraCIM h-R3.

            
	
               

            	
               

            	
               

            
	
              Third
                Party Manufacturer 

            	
               

            	
              Has
                the meaning given in Clause 5.4.

            
	
               

            	
               

            	
               

            
	
              Valid
                Claim 

            	
               

            	
              A
                claim of a patent or patent application that has not expired or been
                held
                invalid or unenforceable by a court of competent jurisdiction in
                a final
                and non-appealable judgment.

            

    

    

    
      	2.	
              Joint
                Development Team

            

    

    

    
      	2.1	
              Formation.
                Within fifteen (15) days after the Commencement Date, the Development
                Team
                Parties shall establish a Joint Development Team, by each Development
                Team
                Party designating its initial members to serve on the Joint Development
                Team and notifying the other Development Team Party of its dates
                of
                availability for the first meeting of the Joint Development Team.
                The
                purpose of the Joint Development Team shall be to oversee the development
                of Licensed Product for purposes of commercialisation in the Oncoscience
                Field and Territory. The Joint Development Team shall consist of
                not more
                than three (3) representatives designated by each Development Team
                Party.
                Each representative shall have relevant and appropriate expertise
                in order
                to oversee the development of the Licensed Product. If a representative
                of
                a Development Team Party is unable to attend a meeting of the Joint
                Development Team, such Development Team Party may designate an alternate
                to attend such meeting. In addition, each Development Team Party
                may, at
                its discretion, invite a reasonable number of other employees, consultants
                or scientific advisors to attend the meetings of the Joint Development
                Team, provided that such invitees are bound by appropriate confidentiality
                obligations. Each Development Team Party may change one or all of
                its
                representatives to the Joint Development Team at any time upon notice
                to
                the other Development Team Party.

            

    

    

    
      	2.2	
              Meetings.
                The Joint Development Team shall meet quarterly and at such other
                times as
                the Parties may agree. The first meeting of the Joint Development
                Team
                shall be held as soon as reasonably practicable, but in no event
                later
                than 30 days after the Commencement Date. Meetings shall be held
                at such
                place or places as are mutually agreed or by teleconference or
                videoconference; provided, however, that there shall be at least
                one
                face-to-face meeting per calendar
                year.

            

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    
      	2.3	
              Responsibilities.
                During the Development Term, the Joint Development Team
                shall:

            

    

    

    
      	
            	(a)	
              elaborate
                the Development Commercialisation Plan in accordance with Clause
                3.1

            

    

    

    
      	
            	(b)	
              review
                and unanimously approve (or, if the members of the Joint Development
                Team
                are unable to reach unanimous agreement, recommend to the Parties)
                the
                overall
                development strategy for Licensed Product in the Oncoscience Field
                and
                Territory
                (including, without limitation, setting criteria for progression
                of
                Licensed
                Product to the next stage of development under the Development and
                Commercialisation
                Plan);

            

    

    

    
      	
            	(c)	
              review
                and recommend to the Parties modifications to the Development and
                Commercialisation Plan (including the resources to be allocated and
                the
                timelines contained in the Development and Commercialisation
                Plan);

            

    

    

    
      	
            	(d)	
              facilitate
                the transfer of Know-How between the Parties for purposes of conducting
                the Development and Commercialisation
                Plan;

            

    

    

    
      	
            	(e)	
              regularly
                assess the progress of Oncoscience in its conduct of the Development
                and
                Commercialisation Plan; and

            

    

    

    
      	
            	(f)	
              perform
                such other activities as are contemplated under this Clause 2 and
                Clause
                1. For the avoidance of doubt the Joint Development Team shall not
                have
                any role or responsibility in relation to determining whether Oncoscience
                has complied or will comply with its obligations to CIMYM under Clauses
                3
                or 8.

            

    

    

    
      	2.4	
              Disputes.
                If agreement cannot be reached within the Joint Development Team,
                Oncoscience shall have the right to make the final determination
                concerning the resolution of the disagreement. Notwithstanding the
                foregoing, in the case of a disagreement involving a material matter,
                prior to invoking its rights under this Clause 2.4, Oncoscience agrees
                to
                have its chief executive contact the chief executive of CIMYM for
                the
                purpose of discussing the disagreement and attempting to reach a
                consensus. It shall be the goal of the chief executives to reach
                a
                consensus within five (5) days of the date on which contact is initiated
                by the chief executive of Oncoscience, it being understood that (i)
                in the
                event of an extraordinary circumstance requiring a faster resolution
                (e.g., a safety issue or extraneous timing issue), Oncoscience shall
                have
                the right to make the final determination prior to the end of such
                five
                (5) day period if a consensus has not been achieved by the required
                time
                for resolution and (ii) in the event that a consensus has not been
                achieved within ten (10) days of the date on which contact is initiated
                by
                the executive officer of Oncoscience, Oncoscience shall have the
                right to
                make the final determination. For the avoidance of doubt, Oncoscience
                shall not have any right, under this clause, to determine whether
                it has
                complied or will comply with its obligations to CIMYM under Clauses
                2.4 or
                8.

            

    

    

    
      	3.	
              Development
                and Commercialisation

            

    

    

    
      	3.1	
              Development
                and Commercialisation Plan.

            

    

    

    
      	3.1.1	
              Within
                90 days of the Commencement Date, the Joint Development Team shall
                prepare
                a written plan (“Development and Commercialisation Plan”) that expands
                upon the initial development plan set out in Schedule 3 and will
                describe,
                and provide a timeline for:

            

    

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    
      	
            	(a)	
              all
                development activities for the Licensed Product in the Oncoscience
                Field
                and Territory, addressing each phase of development and the budget
                for
                completion of such activities, and providing detailed information
                on the
                activities to be conducted in the next 12 month
                period;

            

    

    

    
      	
            	(b)	
              intellectual
                property protection strategy, including applying for Orphan Drug
                Status,
                patents and supplementary protection
                certificates

            

    

    

    
      	
            	(c)	
              sub-licensing
                strategy;

            

    

    

    
      	
            	(d)	
              clinical
                and registration strategy, with a view to expediting regulatory approval
                for Licensed Product; and

            

    

    

    
      	
            	(e)	
              commercialisation
                strategy.

            

    

    

    
      	3.1.2	
              The
                Joint Development Team shall update the Development and Commercialisation
                Plan on a regular basis (and at least
                annually).

            

    

    

    
      	3.2	
              Development
                and commercialisation activities.
                Oncoscience shall be responsible for the development and commercialisation
                (in accordance with the Development and Commercialisation Plan) of
                the
                Licensed Product in the Oncoscience Field and Territory. Such development
                and commercialisation shall be carried out under the oversight and
                management of the Joint Development Team and in accordance with the
                provisions of this Agreement.

            

    

    

    
      	3.3	
              Development
                and commercialisation costs.
                Oncoscience shall bear all costs associated with the development
                and
                commercialisation of Licensed Product in the Oncoscience Field and
                Territory, including costs incurred in the Development and
                Commercialisation Plan. If any Providing Party agrees with Oncoscience
                to
                conduct work as part of the Development and Commercialisation Plan
                (which
                may include advice given to the Joint Development Team), the Providing
                Party’s costs of conducting such work shall be borne by Oncoscience, with
                the time costs of the Providing Party’s representatives being charged to
                Oncoscience on a daily rate basis. The Providing Party’s daily rate for
                its representatives in the work referred to in the previous sentence
                shall
                be agreed between the Parties or, if they are unable to agree, the
                rate
                shall be US$ 1,000 (one thousand US dollars) per day plus any
                product-related consumable costs and external costs associated with
                such
                work.

            

    

    

    
      	3.4	
              Reporting.
                Without prejudice to the generality of Oncoscience’s obligations under
                Clauses 8.1 and 9.2, Oncoscience shall provide a report (“Development and
                Commercialisation Report”) to CIMYM at least annually to CIMYM. In
                addition, Oncoscience shall provide to CIMYM a quarterly, written
                status
                update on all clinical, development and commercial activities being
                undertaken, and from time to time upon request, showing all past,
                current
                and projected activities taken or to be taken by Oncoscience to bring
                Licensed Product to market and maximise the sale of Licensed Product
                in
                the Oncoscience Field and Territory, and including details of all
                Arising
                Intellectual Property. CIMYM’s receipt or approval of any such report
                shall not be taken to waive or qualify Oncoscience’s obligations under
                Clause 8.1.

            

    

    

    
      	3.5	
              Exchange
                of data.
                It is CIMYM’s or CIMAB’s intention to grant licences to commercialise
                TheraCIM h-R3 in the CIMYM Field and Territory. Accordingly, each
                of the
                Parties or its licensee(s), may generate data in relation to Licensed
                Products that is useful to the other Parties in connection with their
                commercialisation of Licensed Products. To facilitate such
                commercialisation, Oncoscience shall disclose and provide to CIMYM
                and
                CIMAB all Arising Intellectual Property in accordance with the provisions
                of Clause 3.4. CIMYM (or CIMAB as applicable) and Oncoscience shall
                use
                reasonable efforts to reach agreement with CIMYM’s (or CIMAB’s as
                applicable) other licensee(s) of TheraCIM h-R3 for the disclosure
                to
                Oncoscience of clinical data in respect of TheraCIM h-R3 that is
                generated
                by such licensee(s).

            

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    

    
      	4.	
              Know-how
                and Confidential
                Information

            

    

    

    
      	4.1	
              Provision
                of Know-how.
                Upon Oncoscience’s reasonable request, CIMYM shall supply Oncoscience with
                all Licensed Know-how in its possession that is specifically relevant
                to
                the development and commercialisation of TheraCIM h-R3 and that CIMYM
                is
                at liberty to disclose and has not previously been disclosed and
                which is
                reasonable necessary to enable Oncoscience to undertake the further
                development of Licensed Product. The Licensed Know-how shall be subject
                to
                the confidentiality provisions of Clause 4.4. The method of any such
                supply shall be as specified in Schedule 2 but shall not require
                CIMYM to
                undertake more than 5 man-days of work, unless otherwise agreed in
                writing
                between the Parties.

            

    

    

    
      	4.2	
              Status
                of Know-how.
                Oncoscience acknowledges that the Licensed Know-how is subject to
                further
                development. Accordingly, specific results cannot be guaranteed and
                any
                results, materials, information or other items, including the Licensed
                Know-how and inventions claimed in the Licensed Patent Rights (together
                “Delivered Items”) provided under this Agreement are provided “as is” and
                without any express or implied warranties, representations or
                undertakings. As examples, but without limiting the foregoing, CIMYM
                does
                not give any warranty that Delivered Items are of merchantable or
                satisfactory quality, are fit for any particular purpose, comply
                with any
                sample or description, or are viable, uncontaminated, safe or
                non-toxic.

            

    

    

    
      	4.3	
              Use
                of Know-how.
                Oncoscience undertakes that for a period of 10 years from the date
                of
                first commercial sale of Licensed Product in the Territory or for
                so long
                as any substantial part of the Know-how remains subject to the obligations
                of confidence of Clause 4.4, whichever is the shorter, it will not
                use the
                Licensed Know-how for any purpose except as expressly licensed hereby
                and
                in accordance with the provisions of this
                Agreement.

            

    

    

    
      	4.4	
              Confidentiality
                obligations.
                Each Party (“Receiving Party”)
                undertakes:

            

    

    

    
      	
            	(a)	
              to
                maintain as secret and confidential all Know-how and other technical
                or
                commercial information obtained directly or indirectly from the other
                Party (“Disclosing Party”) in the course of or in anticipation of this
                Agreement and to respect the Disclosing Party’s rights
                therein,

            

    

    

    
      	
            	(b)	
              to
                use the same exclusively for the purposes of this Agreement,
                and

            

    

    

    
      	
            	(c)	
              to
                disclose the same only to those of its employees, contractors and
                sub-licensees pursuant to this Agreement (if any) to whom and to
                the
                extent that such disclosure is reasonably necessary for the purposes
                of
                this Agreement.

            

    

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    
      	4.5	
              Exceptions
                to obligations.
                The provisions of Clause 4.4 shall not apply to Know-how and other
                information which the Receiving Party can demonstrate by reasonable,
                written evidence:

            

    

    

    
      	
            	(a)	
              was,
                prior to its receipt by the Receiving Party from the Disclosing Party,
                in
                the possession of the Receiving Party and at its free disposal;
                or

            

    

    

    
      	
            	(b)	
              is
                subsequently disclosed to the Receiving Party without any obligations
                of
                confidence by a third party who has not derived it directly or indirectly
                from the Disclosing Party; or

            

    

    

    
      	
            	(c)	
              is
                or becomes generally available to the public through no act or default
                of
                the Receiving Party or its agents, employees, Affiliates or
                sub-Licensees.

            

    

    

    
      	4.6	
              Disclosure
                to court, etc.
                If the Receiving Party is required to disclose confidential information
                to
                the courts of any competent jurisdiction, or to any government regulatory
                agency or financial authority, such disclosure shall not be a breach
                of
                Clause 4.4, provided that the Receiving Party shall (i) inform the
                Disclosing Party as soon as is reasonably practicable, and (ii) at
                the
                Disclosing Party’s request seek to persuade the court, agency or authority
                to have the information treated in a confidential manner, where this
                is
                possible under the court, agency or authority’s
                procedures.

            

    

    

    
      	4.7	
              Disclosure
                to employees. The Receiving Party shall procure that all of its
                employees, contractors, consultants, advisers and sub-licensees pursuant
                to this Agreement (if any) who have access to any of the Disclosing
                Party’s information to which Clause 4.4 applies, shall be made aware of
                and subject to these obligations and shall have entered into written
                undertakings of confidentiality at least as restrictive as Clauses
                4.4 and
                4.5 and which apply to the Disclosing Party’s
                information.

            

    

    

    
      	5.	
              Manufacturing
                and supply

            

    

    

    
      	5.1	
              Clinical
                supply.
                CIMAB shall supply to Oncoscience, and Oncoscience shall purchase
                from
                CIMAB, for its own use and that of its Affiliates and sub-licensees,
                in
                finished form with one hundred percent (100%) of Oncoscience’ s
                requirements of TheraCIM h-R3 and Licensed Product for all clinical
                development purposes. Such clinical requirements shall be supplied
                to
                Oncoscience:

            

    

    

    
      	
            	(a)	
              In
                respect of Oncoscience’s requirements for clinical trials for the purposes
                of seeking Regulatory Approvals in the Field in the Territory, at
                a supply
                price of US$ 500 (five hundred US dollars) per gram. Payment will
                be made
                50% in advance for each instalment of product that is ordered under
                this
                paragraph (a) when it is available for delivery. The second half
                of
                payment will be paid within 30 days after receiving the
                product.

            

    

    

    
      	
            	(b)	
              For
                all other supply for clinical purposes (including without limitation
                supply for Phase IV studies and for studies that are not required
                for
                obtaining Regulatory Approvals), a supply price equal to US$1,100
                (one
                thousand one hundred US dollars) per
                gram.

            

    

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    
      	5.2	
              Commercial
                Supply.

            

    

    

    
      	5.2.1	
              CIMAB
                shall supply to Oncoscience, and Oncoscience shall purchase from
                CIMAB, as
                active pharmaceutical ingredient, or if the Parties mutually agree
                at the
                time of entering into the supply agreement described in Clause 5.5, in
                finished form with one hundred percent (100%) of Oncoscience’s
                requirements of Licensed Products for all commercial purposes. CIMAB
                may
                elect to have such requirements supplied to Oncoscience by one or
                more of
                CIMAB’s Contract Manufacturer(s). In such case, the supply agreement to
                be
                entered into shall be concluded nonetheless between Oncoscience and
                CIMAB
                and not between Oncoscience and CIMAB’s Contract Manufacturer(s).
                Oncoscience’s quantity requirements shall include those of its Affiliates
                and sub-licensees. The supply price for the Licensed Product payable
                by
                Oncoscience or its Affiliates to CIMAB (the “Supply
                Price”)
                shall be:

            

    

    

    
      	
            	(a)	
              In
                the case of sales of the Licensed Product made directly by Oncoscience
                or
                its Affiliates to a third party other than to its sub-licensees (i)
                until
                the Payment Cap is reached, US$ 1,250 (one thousand two hundred and
                fifty
                US dollars) per gram of Licensed Product and (ii) after the Payment
                Cap is
                reached, as mutually agreed to between the Parties, acting reasonably;
                and

            

    

    

    
      	
            	(b)	
              In
                the case of sales of the Licensed Product made by Oncoscience or
                its
                Affiliates to its sub-licensee(s), US$ 1,250 (one thousand two hundred
                and
                fifty US dollars) per gram of Licensed
                Product.

            

    

    

    
      	5.3	
              Specifications.
                CIMAB undertakes that all Licensed Product supplied to Oncoscience
                will be
                manufactured in accordance with mutually agreed upon specifications
                (inclusive of specifications in an approved Marketing Authorization
                and
                Good Manufacturing Practices of the EMEA the relevant regulatory
                authorities in the other countries in the Territory, and the relevant
                regulatory authorities in the countries of manufacture of the Licensed
                Product, and will not be adulterated or misbranded under applicable
                laws,
                regulations or guidelines, and that the manufacturer will have in
                force
                all necessary Regulatory Approvals for the manufacture of Licensed
                Product
                in accordance with such specifications for the purposes of supply
                and use
                of Licensed Product in all countries of the Territory and will be
                in good
                standing with all Regulatory
                Authorities.

            

    

    

    
      	5.4	
              Right
                to Have Manufactured in Event of Default by
                CIMAB.

            

    

    

    
      	5.4.1	
              In
                the event that CIMAB or CIMAB’s Contract Manufacturer is unwilling or
                unable to manufacture to the specifications required by the relevant
                Regulatory Authority or by the terms of any relevant Regulatory Approval,
                Oncoscience shall have the right to have manufactured by a Third
                Party
                Manufacturer (as defined below) one hundred percent (100%) of its
                own
                clinical and commercial requirements of Licensed Product, in accordance
                with the provisions of Clause 5.4.2. In the event that CIMAB is unable
                to
                supply Oncoscience with its quantity requirements of Licensed Product
                (as
                described in Clause 5.1 to 5.3) for a period of one or more Calendar
                Quarters in any given two year period Oncoscience shall have the
                right to
                have manufactured by a Third Party Manufacturer as defined below
                its own
                clinical and commercial requirements of Licensed Product, in accordance
                with the provisions of Clause 5.4.2, but Oncoscience shall continue
                to
                purchase at least 50% of its quantity requirements from CIMAB or
                CIMAB’s
                Contract Manufacturer for as long as it is willing and able to do
                so.

            

    

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    
      	5.4.2	
              To
                enable Oncoscience to have Licensed Product manufactured for it in
                accordance with Clause 5.4.1, the Parties shall, at the request of
                Oncoscience, make arrangements for the transfer of relevant CIMAB
                manufacturing technology and know-how to a manufacturer nominated
                by
                Oncoscience (“Third Party Manufacturer”). CIMAB shall supply such
                technology and know-how free of charge but without any obligation
                to bear
                any of Oncoscience’s costs. Prior to the transfer of such manufacturing
                technology and know-how, the Third Party Manufacturer shall be required
                to
                enter into an agreement with CIMAB, on terms satisfactory to CIMAB,
                under
                which the Third Party Manufacturer shall undertake to keep CIMAB’s
                manufacturing technology and know-how confidential and to use it
                only for
                the supply of Licensed Product to Oncoscience or its Affiliate or
                sub-licensee and only in circumstances where Clause 5.4.1 applies.
                The
                terms of such agreement between CIMAB and a Third Party Manufacturer
                shall
                be deemed satisfactory to CIMAB if the terms are identical to the
                terms of
                an equivalent agreement between CIMAB and CIMAB’s Contract
                Manufacturer.

            

    

    

    
      	5.5	
              Supply
                Agreement. Licensed Product supplied by CIMAB or CIMAB’s Contract
                Manufacturer(s) to Oncoscience for clinical and commercial purposes
                shall
                be supplied to Oncoscience pursuant to the terms of a separate Supply
                Agreement. Oncoscience and CIMAB shall use good faith efforts to
                negotiate
                and enter into such a supply agreement at least six (6) months prior
                to
                the submission of a Regulatory Application for such Licensed Product
                in
                the Territory. In addition to more detailed terms regarding form
                of
                product, supply price, specifications, shortage of supply and default
                manufacturing rights as are specified in this Clause 5, each Supply
                Agreement shall contain forecast procedures, permitted variances
                from
                forecasted amounts, order and delivery times, quality control and
                quality
                assurance procedures, audits, yield ratios, maintenance of inventory,
                procedures and remedies for rejection of non-conforming product,
                record
                retention, compliance with laws, and other customary provisions.
                The terms
                of the Supply Agreement shall be consistent with the provisions of
                this
                Clause 5, unless otherwise agreed in writing by CIMAB and
                Oncoscience.

            

    

    

    
      	6.	
              Grant
                of rights

            

    

    

    
      	6.1	
              Licensed
                Intellectual Property.

            

    

    

    
      	6.1.1	
              CIMYM
                hereby grants to Oncoscience, subject to the provisions of this
                Agreement:

            

    

    

    
      	
            	(a)	
              an
                exclusive licence in the Oncoscience Field and Territory (except
                that in
                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the
                Field)
                under the Licensed Patent Rights, with the right to sub-license,
                subject
                to Clause 6.4 below, to develop, use and sell Licensed Product but
                only in
                the Oncoscience Field and Territory;
                and

            

    

    

    
      	
            	(b)	
              an
                exclusive licence in the Oncoscience Field and Territory (except
                that in
                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the
                Field)
                to use the Licensed Know-how, with the right to sub-license, subject
                to
                Clause 6.4 below, to develop, use and sell Licensed Product but only
                in
                the Oncoscience Field and Territory;
                and

            

    

    

    
      	
            	(c)	
              an
                exclusive licence in the Oncoscience Field and Territory (except
                that in
                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the
                Field)
                to have Licensed Product manufactured for it by a Third Party
                Manufacturer, but only in the circumstances described in Clause
                5.4.

            

    

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    
      	6.1.2	
              In
                the event that CIMAB wishes to exercise its Co-exclusive rights in
                Russia,
                Belarus or Ukraine, it shall notify Oncoscience of its intended activities
                in such countries, in particular to ensure that Oncoscience’s rights under
                this Agreement are not adversely
                affected.

            

    

    

    
      	6.2	
              Arising
                Intellectual Property (including clinical
                data).

            

    

    

    
      	6.2.1	
              Arising
                Intellectual Property shall be owned by the Party (which for the
                purposes
                of this clause may include CIM) that invents or creates it, and if
                it is
                jointly invented or created by two or more of the Parties it shall
                be
                owned jointly by those Parties in equal, undivided shares, subject
                to the
                provisions of this Agreement including the following
                provisions:

            

    

    

    
      	
            	(a)	
              Recognising
                the contribution that CIM’s scientists have made, and are continuing to
                make, to the development of TheraCIM h-R3 and the current stage of
                its
                development, the Parties anticipate that, as a matter of law, CIM
                scientists should be named as inventor(s) or joint inventor(s) of
                any new
                inventions made under this Agreement. Accordingly, unless the Party
                filing
                a patent application in respect of Arising Intellectual Property
                is
                advised by external patent counsel that such naming would prejudice
                the
                validity of the resulting Arising Patents, all Arising Patents shall
                be
                considered to have been jointly invented by representatives of CIM
                and
                Oncoscience, and accordingly shall be jointly owned by them in equal,
                undivided shares, subject to the provisions of this
                Agreement;

            

    

    

    
      	
            	(b)	
              It
                is anticipated that Arising Know-how will be generated by clinicians
                and
                other Persons in the course of, or arising from, clinical studies
                that
                have been designed by the Joint Development Team. Accordingly, it
                is
                agreed that all Arising know-how developed in, or arising from, the
                work
                performed under the Development and Commercialisation Plan shall
                be
                jointly owned by CIM and Oncoscience in equal, undivided shares,
                subject
                to the provisions of this Agreement;
                and

            

    

    

    
      	
            	(c)	
              Subject
                to paragraphs (a) and (b) above, where Arising Intellectual Property
                consists of an improvement to, or a new application of, Licensed
                Intellectual Property and, as a matter of law, is made solely by
                employees
                of Oncoscience, it shall be owned solely by
                Oncoscience.

            

    

    

    
      	6.2.2	
              CIMAB
                hereby grants and agrees to grant to Oncoscience an exclusive, fully
                paid-up and royalty-free licence under Arising Intellectual Property
                in
                the Oncoscience Field and Territory, with the right to sub-license,
                to
                research, develop, make, have made, import, use, sell and otherwise
                deal
                in any and all products and processes in the Oncoscience Field and
                Territory.

            

    

    

    
      	6.2.3	
              Oncoscience
                hereby grants and agrees to grant to CIMYM and CIMAB an exclusive,
                fully
                paid-up and royalty-free licence under Arising Intellectual Property
                in
                the CIMYM Field and Territory, with the right to sub-license, to
                research,
                develop, make, have made, import, use, sell and otherwise deal in
                any and
                all products and processes in the CIMYM Field and
                Territory.

            

    

    

    
      	6.3	
              Formal
                licences. If requested by Oncoscience, and at Oncoscience’s
                administrative cost, the Parties shall execute such formal licences
                as may
                be necessary or appropriate for registration with Patent Offices
                and other
                relevant authorities in the Territory. In the event of any conflict
                in
                meaning between any such licence and the provisions of this Agreement,
                the
                provisions of this Agreement shall prevail. The Parties shall use
                reasonable endeavours to ensure that, to the extent permitted by
                relevant
                authorities, this Agreement shall not form part of any public
                record.

            

    

    
      
        
        

      

      
        14

        
          

        

      

      
        
        

      

    

    

    
      	6.4	
              Sub-licensing.
                Oncoscience shall be entitled to grant sub-licences (which for the
                purposes of this clause shall include any option or right to acquire
                a
                sub-licence) of its rights under this Agreement to any person (including
                without limitation any Affiliate of Oncoscience), provided
                that:

            

    

    

    
      	
            	(a)	
              Oncoscience
                shall first provide written notice to CIMYM of any request to enter
                into a
                sub-license and shall provide with such notice a copy of the proposed
                sub-license agreement. CIMYM shall provide its response to any such
                request within thirty (30) days of its receipt of Oncoscience’s notice,
                failing which, it shall be deemed to have consented to such request.
                CIMYM
                shall have no reason to withhold its consent to such request provided
                that
                the proposed sub-license agreement complies with the terms of this
                Clause
                6.4. Oncoscience shall provide to the Parties, within thirty (30)
                days of
                its execution, a fully executed copy of the sub-license
                agreement;

            

    

    

    
      	
            	(b)	
              the
                scope of the sub-licence shall not exceed the scope of the licence
                granted
                under this Agreement and, in particular, shall not include any
                manufacturing rights;

            

    

    

    
      	
            	(c)	
              the
                sub-licence shall include obligations on the sub-licensee which are
                equivalent to the obligations on Oncoscience under this Agreement
                (and the
                sub-licensee shall not have any right to grant sub-sub-licences without
                CIMYM’s prior written agreement, which consent may be withheld at CIMYM’s
                sole discretion);

            

    

    

    
      	
            	(d)	
              if
                agreed between CIMYM and the sub-licensee, the sub-licence shall
                continue
                in force as an agreement between CIMYM (in place of Oncoscience)
                and the
                sub-licensee or, if no such agreement is made, the sub-licence shall
                terminate automatically on the termination of this Agreement for
                any
                reason;

            

    

    

    
      	
            	(e)	
              clinical
                trials in the territory of the sub-licensee shall commence not later
                than
                18 months from the date of the conclusion of the sub-licence agreement,
                failing which the sub-licence shall automatically
                terminate;

            

    

    

    
      	
            	(f)	
              Oncoscience
                shall have no ownership interest of any kind in the proposed sub-licensee;
                and

            

    

    

    
      	
            	(g)	
              Oncoscience
                shall be responsible for any breach of the sub-licence by the
                sub-licensee, as if the breach had been that of Oneoscience under
                this
                Agreement, and Oncoscience shall indemnify CIMYM against any loss,
                damages, costs, claims or expenses which are awarded against or suffered
                by CIMYM as a result of any such breach by the
                sub-licensee.

            

    

    

    
      	6.5	
              Reservation
                of rights within Field and Territory.
                For the avoidance of doubt, CIMYM reserves
                the right for itself and its licensees and assigns to use TheraCIM
                h-R3
                and the Licensed Intellectual Property in the Oncoscience Field and
                Territory with the prior consent of Oncoscience (a) for the purposes
                of
                research; and/or (b) for the purposes of development (including clinical
                trials) of products with a view to obtaining regulatory approval
                for such
                products in the CIMYM Field and Territory. If CIMYM wishes to conduct
                research or development activities in the Oncoscience Field and Territory
                in accordance with the provisions of this clause, it will so inform
                Oncoscience and give Oncoscience a first opportunity to propose terms
                for
                an agreement with CIMYM under which Oncoscience would assist CIMYM
                with
                such activities at the cost of CIMYM. It is understood and agreed
                that
                CIMYM will be required under regulatory GCP to retain archive samples
                of
                materials.

            

    

    
      
        
        

      

      
        15

        
          

        

      

      
        
        

      

    

    

    
      	6.6	
              No
                other licence.
                It is acknowledged and agreed that no licence is granted by CIMYM
                to
                Oncoscience other than the licence(s) expressly granted by the provisions
                of this Clause 6. Without prejudice to the generality of the foregoing
                CIMYM reserves all rights under the Licensed Intellectual Property
                in the
                CIMYM Field and Territory.

            

    

    

    
      	6.7	
              Quality.
                Oncoscience shall ensure that all Licensed Product marketed by it
                and its
                sub-licensees is of satisfactory quality and complies with all applicable
                laws and regulations in each part of the
                Territory.

            

    

    

    
      	6.8	
              Acknowledgment
                by CIMAB.
                CIMAB acknowledges and agrees that CIMYM has been granted the necessary
                rights and licences to enable it to grant the licences referred to
                in
                Clauses 6.1. and 6.4 of this
                Agreement.

            

    

    

    
      	6.9	
              Acknowledgment
                by CIMYM and CIMAB.
                CIMYM and CIMAB acknowledge and agree that, subject to Clause 6.4(g),
                Oncoscience is free to organize its distribution of the Licensed
                Product
                and determine its sales price of the Licensed Product within the
                Oncoscience Field and Territory at its own discretion. Oncoscience
                is also
                free to determine its sales price vis-à-vis its sub-licensees. However,
                only for the purpose of calculating the royalties pursuant to Article
                7 of
                this Agreement the supply price charged by Oncoscience to its
                sub-licensees shall be deemed $ 2,312.50 (two thousand three hundred
                and
                twelve US dollars and fifty cents) per gram if and as far as Oncoscience
                charges a supply price to its sub-licensees which is below the threshold
                of $ 2,312.50 (two thousand three hundred and twelve US dollars and
                fifty
                cents) per gram.

            

    

    

    
      	7.	
              Payments

            

    

    

    
      	7.1	
              Payments
                prior to reaching Payment Cap.
                Until such time as the total amount of payments made by Oncoscience
                to
                CIMYM under this Clause 7.1 reaches US$[*] ([*] US dollars) (excluding
                VAT
                or other taxes or charges and excluding the amount of any payments
                from
                Oncoscience to CIMYM in respect of the supply of products, materials
                or
                services) (the “Payment Cap”), Oncoscience shall pay to CIMYM the
                following amounts:

            

    

    

    
      	
            	(a)	
              [*]%
                ([*] percent) of all Milestone Receipts, which shall be payable within
                30
                (thirty) days of any such Milestone Receipt being received by Oncoscience
                or its Affiliate;

            

    

    

    
      	
            	(b)	
              In
                the case of sales of the Licensed Product made directly by Oncoscience
                or
                its Affiliates to a third party other than its
                sub-licensee(s):

            

    

    

    
      	
            	(i)	
              a
                royalty of [*]% ([*] percent) of Net Sales Value of all Licensed
                Product;
                and

            

    

    

    
      	
            	(ii)	
              an
                additional royalty of US$ [*] ([*] US dollars) per gram of the
                Licensed Product; and

            

    

    
      
        
        

      

      
        16

        
          

        

      

      
        
        

      

    

    
      	
            	(c)	
              In
                the case of sales of the Licensed Product made by Oncoscience or
                its
                Affiliates to its sub-licensee(s), a royalty of [*]% of Net Sales
                Value of
                all Licensed Product.

            

    

    

    
      	7.2	
              Payments
                after reaching Payment Cap.

            

    

    

    
      	7.2.1	
              Royalties.
                After the total amount of payments made by Oncoscience to CIMYM under
                Clause 7.1 has reached the Payment Cap, Oncoscience shall pay to
                CIMYM the
                following amounts:

            

    

    

    
      	
            	(a)	
              [*]%
                ([*] percent) of all Milestone Receipts, which shall be payable
                within 30 (thirty) days of any such Milestone Receipt being received
                by Oncoscience or its Affiliates;

            

    

    

    
      	
            	(b)	
              In
                the case of sales of the Licensed Product made directly by Oncoscience
                or
                its Affiliates to a third party other than its sub-licensee(s), a
                royalty
                on cumulative Gross Sales Value of Licensed Product in each Calendar
                Year,
                at the following incremental rates:

            

    

    

    
      	
              Incremental
                Gross Sales Value in Calendar Year

            	 	
              Royalty
                rate

            	 
	
              Less
                than or equal to US$[*]

            	 	 	
              [*]

            	
              %

            
	
              Greater
                than US$[*] and 

              less
                than or equal to US$[*]

            	 	 	
              [*]

            	
              %

            
	
              Greater
                than US$[*] and 

              less
                than or equal to US$[*]

            	 	 	
              [*]

            	
              %

            
	
              Greater
                than US$[*]

            	 	 	
              [*]

            	
              %

            

    

    

    Example:
      If in a particular Calendar Year, cumulative Gross Sales Value amounts to
      US$[*], the following royalties would be payable under this Clause:

    

    
      	
              (i)
                

            	 	[*]%
              on the first US$175M of Gross Sales Value = 	 	
               

            	
              US$[*]

            	 
	
              (ii)
                

            	 	[*]%
              on the next US$175M of Gross Sales Value = 	 	
               

            	
              US$[*]

            	 
	
              (iii)
                

            	 	[*]%
              on the remaining US$20M of Gross Sales Value= 	 	
               

            	
              US$[*]

            	 
	
              (iv)
                

            	 	Total
              amount of royalty due in Calendar Year = 	 	
               

            	
              US$[*]

            	; 

    

    

    and

    

    
      	
            	(c)	
              In
                the case of sales of the Licensed Product made by Oncoscience or
                its
                Affiliates to
                its sub-licensee(s), a royalty of [*]% of Net Sales Value of all
                Licensed
                Product.

            

    

    

    
      	7.3	
              Payment
                dates. Royalties due under this Agreement shall be paid within 90
                days of the end of each Calendar Quarter, in respect of sales of
                Licensed
                Product made during such Calendar Quarter, and within 120 days of
                the
                termination of this Agreement.

            

    

    

    
      	7.4	
              Payment
                terms. All sums due under this
                Agreement:

            

    

    

    
      	
            	(a)	
              are
                exclusive of Value Added Tax which where applicable will be paid
                by
                Oncoscience to CIMYM in addition;

            

    

    

    
      	
            	(b)	
              shall
                be paid in US dollars (or such other currency as the Parties may
                agree)
                and, in the case of sales or sub-license income received by Oncoscience
                in
                a currency other than US dollars, the income shall be calculated
                in the
                other currency and then converted into equivalent US dollars at the
                purchasing rate for US dollars as quoted by Kreissparkasse Sűdholstein,
                Friedrich-Ebert-Damm 38-40 25431 Pinneberg in Germany as at the close
                of
                business on the last business day of the quarterly period with respect
                to
                which the payment is made;

            

    

    
      
        
        

      

      
        17

        
          

        

      

      
        
        

      

    

    

    
      	
            	(c)	
              shall
                be made without deduction of income tax or other taxes charges or
                duties
                that may be imposed, except insofar as Oncoscience is required to
                deduct
                the same to comply with applicable laws. The Parties shall cooperate
                and
                take all steps reasonably and lawfully available to them to avoid
                deducting such taxes and to obtain double taxation relief. If Oncoscience
                is required to make any such deduction it shall provide CIMYM with
                such
                certificates or other documents as it can reasonably obtain to enable
                CIMYM to obtain appropriate relief from double taxation of the payment
                in
                question; and

            

    

    

    
      	
            	(d)	
              shall
                be made by the due date, failing which CIMYM may charge interest
                on any
                outstanding amount on a daily basis at a rate equivalent to 3% above
                the
                US prime lending rate then in
                force.

            

    

    

    
      	7.5	
              Exchange
                controls, etc.
                If at any time during the continuation of this Agreement Oncoscience
                is
                prohibited from making any of the payments required hereunder by
                a
                governmental authority in any country then Oncoscience will within
                the
                prescribed period for making the said payments in the appropriate
                manner
                use its best endeavours to secure from the proper authority in the
                relevant country permission to make the said payments and will make
                them
                within 7 days of receiving such permission. If such permission is
                not
                received within 30 (thirty) days of Oncoscience making a request
                for such
                permission then, at the option of CIMYM, Oncoscience shall deposit
                the
                royalty payments due in the currency of the relevant country either
                in a
                bank account designated by CIMYM within such country or such royalty
                payments shall be made to an associated company of CIMYM designated
                by
                CIMYM and having offices in the relevant country designated by
                CIMYM.

            

    

    

    
      	7.6	
              Royalty
                statements.
                Oncoscience shall send to CIMYM at the same time as each royalty
                payment
                is made in accordance with Clause 7.3 a statement setting out, in
                respect
                of each country in which Licensed Product is sold, the types of Licensed
                Product sold, the quantity of each type sold, and the total Gross
                Sales
                Value and Net Sales Value, in respect of each type, expressed both
                in
                local currency and US dollars and showing the conversion rates used,
                during the period to which the royalty payment
                relates.

            

    

    

    
      	7.7	
              Records

            

    

    

    
      	7.7.1	
              Oncoscience
                shall keep at its normal place of business detailed and up to date
                records
                and accounts showing the quantity, description and Gross Sales Value
                of
                Licensed Product, all the documents corresponding to the deductions,
                and
                the amount of Milestone Receipts received by it in respect of Licensed
                Product, on a country by country basis, and being sufficient to ascertain
                the payments due under this
                Agreement.

            

    

    

    
      	7.7.2	
              Oncoscience
                shall make such records and accounts available, on reasonable notice,
                for
                inspection during business hours by an independent chartered accountant
                nominated by CIMYM for the purpose of verifying the accuracy of any
                statement or report given by Oncoscience to CIMYM under Clause 7.6.
                The
                accountant shall be required to keep confidential all information
                learnt
                during any such inspection, and to disclose to CIMYM only such details
                as
                may be necessary to report on the accuracy of Oncoscience’s statement or
                report. CIMYM shall be responsible for the accountant’s charges unless the
                accountant certifies that there is an inaccuracy of more than 5%
                (five
                percent) in any royalty statement, in which case Oncoscience shall
                pay his
                charges in respect of that inspection. If the inspection shows that
                Oncoscience owes a payment to CIMYM under this Agreement, Oncoscience
                shall promptly make such
                payment.

            

    

    
      
        
        

      

      
        18

        
          

        

      

      
        
        

      

    

    

    
      	7.7.3	
              Oncoscience
                shall ensure that CIMYM has the same rights as those set out in this
                Clause 7.7 in respect of any Affiliate or sub-licensee of Oncoscience
                that
                is sub-licensed under Licensed Intellectual Property pursuant to
                this
                Agreement.

            

    

    

    
      	8.	
              Diligence

            

    

    

    
      	8.1	
              Oncoscience
                shall use Diligent and Reasonable Efforts to develop and commercially
                exploit Licensed Product to the maximum extent throughout the Territory.
                Without limiting Oncoscience’s obligations under the previous sentence of
                this Clause 8.1, Oncoscience shall develop and commercially exploit
                Licensed Product in accordance with the Development and Commercialisation
                Plan.

            

    

    

    
      	8.2	
              If
                CIMYM considers at any time during the period of this Agreement that
                Oncoscience has without legitimate reason failed to comply with its
                obligations under Clause 8.1, CIMYM shall be entitled to refer to
                an
                independent expert the following
                questions:

            

    

    

    
      	
            	(a)	
              whether
                Oncoscience has complied with such obligations; and if
                not

            

    

    

    
      	
            	(b)	
              what
                specific action Oncoscience should have taken (“Specific
                Action”) in order to have so
                complied.

            

    

    

    
      	8.3	
              The
                independent expert shall be appointed in accordance with the provisions
                of
                Schedule 4 and his decision shall be final and binding on the
                Parties.

            

    

    

    
      	8.4	
              If
                the expert determines that Oncoscience has failed to comply with
                its
                obligations under this Clause 8, and if Oncoscience fails to take
                the
                Specific Action within 6 months of the expert giving his decision
                in
                accordance with Schedule 4, CIMYM shall be entitled, by giving, at
                any
                time within 3 months after the end of that 6 month period, not less
                than 3
                months’ notice to terminate this Agreement and the licences granted to
                Oncoscience under Clause 6.

            

    

    

    
      	9.	
              Intellectual
                property

            

    

    

    
      	9.1	
              Obtain
                and maintain the Licensed Patent Rights. CIMYM shall, at its cost and
                expense:

            

    

    

    
      	
            	(a)	
              Diligently
                seek to obtain valid patents in the name of CIM pursuant to each
                of the
                patent applications listed in Schedule 1;
                and

            

    

    

    
      	
            	(b)	
              pay
                all renewal fees in respect of the Licensed Patent Rights as and
                when due;
                

            

    

      

    
      provided
        that if CIMYM elects to abandon any such application or not to maintain any
        such
        Licensed Patent (or cease funding such application or patent) it shall give
        3
        months’ prior written notice to Oncoscience and on the expiry of such notice
        period CIMYM shall cause the patent or patent application in question to
        be
        assigned to Oncoscience and CIM shall have no continuing rights under such
        Licensed Patents. 

    

    

    
      	9.2	
              Obtain
                and maintain the Arising Patents. The Parties shall consult with one
                another in relation to the filing and maintenance of any Arising
                Patents
                in respect of any inventions made by Oncoscience, its Affiliates
                or
                sub-licensees that relate to any of the Licensed Intellectual Property
                or
                the Licensed Product (“Arising Inventions”). Oncoscience shall or shall
                ensure that its Affiliate or sub-licensee shall, at its own cost
                and
                expense:

            

    

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

    

    
      	
            	(a)	
              Diligently
                seek to obtain valid patents (in the name of the relevant Parties
                as
                specified in Clause 6.2.1) in respect of any Arising Inventions;
                and

            

    

    

    
      	
            	(b)	
              pay
                all renewal fees in respect of the Arising Patents as and when due;
                

            

    

    

    provided
      that if Oncoscience its Affiliate or sub-licensee wishes to abandon any such
      application or not to maintain any such Arising Patent (or to cease finding
      such
      application or patent) Oncoscience shall give 3 months’ prior written notice to
      CIMYM and on the expiry of such notice period Oncoscience shall cause the patent
      or patent application in question to be assigned to CIM and Oncoscience shall
      have no continuing rights under such Arising Patents.

    

    
      	9.3	
              Infringement
                of the Patents

            

    

    

    
      	9.3.1	
              Each
                Party shall inform the other Party promptly if it becomes aware of
                any
                infringement or potential infringement of any of the Patents in the
                Oncoscience Field and Territory, and the Parties shall consult with
                each
                other to decide the best way to respond to such
                infringement.

            

    

    

    
      	9.3.2	
              Oncoscience
                shall be responsible, at its discretion, for taking action against
                infringers of the Licensed Patents in the Oncoscience Field and Territory
                at its sole expense, and it shall be entitled to retain any damages
                or
                other payments or benefits obtained by such action in the Oncoscience
                Field and Territory, after reimbursing CIMYM and CIMAB for any reasonable
                expenses incurred in assisting it in such action. If Oncoscience
                declines
                to take action, then CIMYM shall be entitled to take action against
                the
                third party at CIMYM’s sole expense and CIMYM shall be entitled to all
                damages or other sums received from such action, after reimbursing
                Oncoscience for any reasonable expenses incurred in assisting it
                in such
                action. If the alleged infringement is both within and outside the
                Oncoscience Field and Territory, the Parties shall also co-operate
                with
                CIMYM’s and CIMAB’s other licensees (if any) in relation to any such
                action and shall divide the costs of such action proportionately
                among
                Oncoscience and CIMYM’s and CIMAB’s other licensees who participate in
                such action. The apportionment of costs between licensees shall be
                decided
                by CIMYM, acting reasonably.

            

    

    

    
      	9.4	
              Infringement
                of third party rights

            

    

    

    
      	9.4.1	
              If
                any warning letter or other notice of infringement is received by
                a Party,
                or legal suit or other action is brought against a Party, alleging
                infringement of third party rights in the manufacture, use or sale
                of the
                Licensed Product or use of any Patents, that Party shall promptly
                provide
                full details to the other Party, and the Parties shall discuss the
                best
                way to respond.

            

    

    

    
      	9.4.2	
              CIMYM
                shall have the right but not the obligation to defend such suit and
                shall
                have the right to settle with such third party, provided that if
                any
                action or proposed settlement involves the making of any statement,
                express or implied, concerning the validity of any Patent, the consent
                of
                Oncoscience must be obtained before taking such action or making
                such
                settlement, such consent not to be unreasonably withheld or
                delayed.

            

    

    
      
        
        

      

      
        20

        
          

        

      

      
        
        

      

    

    
      	9.5	
              Third
                party intellectual property.
                For the avoidance of doubt Oncoscience shall be solely responsible
                for
                obtaining and paying for any additional licences and other rights
                that may
                be required to enable Oncoscience, its Affiliates or sub-licensees
                to
                commercialise Licensed Product in the Territory. If the sale of TheraCIM
                h-R3 is found to infringe the intellectual property rights of a third
                party, and results in the payment of royalties or other compensation
                by
                Oncoscience (or its Affiliate or sub-licensee) to the third party,
                Oncoscience may reduce its royalty payments to CIMYM, the reduction
                to be
                in the amount of [*]% ([*] percent) of the royalties or other compensation
                paid to the third party in respect of sales of Licensed Product in
                the
                Territory, subject to the following
                conditions:

            

    

    

    
      	
            	(a)	
              The
                reduction shall not exceed [*]% ([*] percent) of Net Sales Value
                with
                respect to the country(ies) in the Territory for which payments are
                being
                made to the third party. For example, if in the absence of this Clause
                the
                royalty due from Oncoscience to CIMYM on the sale of a Licensed Product
                is
                [*]% ([*] percent) of Net Sales Value, the royalty following such
                deduction shall not be reduced below [*]% ([*]
                percent).

            

    

    

    
      	
            	(b)	
              Such
                reductions shall only be made where the third party liability arises
                from
                the use of the inventions claimed in the Licensed Patents and shall
                not be
                made in respect of any other inventions, improvements or other features
                that Oncoscience chooses to incorporate into the Licensed
                Product.

            

    

    

    
      	9.6	
              Product
                names.
                Oncoscience shall be responsible for deciding, in consultation with
                CIMYM,
                the trade mark to be applied to the Licensed Product in the Oncoscience
                Field and Territory. Oncoscience will be responsible for applying
                for any
                such trade mark in the Territory at its sole cost. CIMYM acknowledges
                that
                it has no objection against the trade mark “Theraloc”. CIMYM will be
                responsible for applying for an international, non-proprietary name
                (“INN”) for the Licensed Product at its sole cost. Oncoscience
                acknowledges that it has no objection to the INN
                “CIMAZUMAB”.

            

    

    

    
      	10.	
              Warranties
                and liability

            

    

    

    
      	10.1	
              Warranties
                by CIMYM.
                CIMYM warrants that:

            

    

    

    
      	
            	(a)	
              subject
                to Clause 10.4, it is the owner or exclusive licensee of the Licensed
                Patent Rights; and

            

    

    

    
      	
            	(b)	
              it
                has not done, and will not do nor agree to do during the continuation
                of
                this Agreement, any of the following things if to do so would be
                inconsistent with the exercise by Oncoscience of the rights granted
                to it
                under this Agreement, namely:

            

    

    

    
      	
            	(i)	
              grant
                or agree to grant any rights in the Licensed Patent Rights in the
                Oncoscience Field and Territory; or

            

    

    

    
      	
            	(ii)	
              assign,
                mortgage, charge or otherwise transfer any of the Licensed Patent
                Rights;
                and

            

    

    

    
      	
            	(c)	
              it
                is not aware (but without having carried out any searches or
                investigations) that any third party (other than CIMYM’s licensor(s)) owns
                or claims any rights in the Licensed Patent
                Rights.

            

    

    
      
        
        

      

      
        21

        
          

        

      

      
        
        

      

    

    
      	10.2	
              Warranty
                by Oncoscience.
                Oncoscience warrants and undertakes (a) that it has, and will continue
                to
                have sufficient financial and other resources to fulfil its obligations
                under this Agreement, and (b) that it has obtained all necessary
                authorisations from its supervisory board and investors to use such
                resources and fulfil such
                obligations.

            

    

    

    
      	10.3	
              No
                other warranties

            

    

    

    
      	10.3.1	
              Each
                of Oncoscience and CIMYM acknowledges that, in entering into this
                Agreement, it does not do so in reliance on any representation, warranty
                or other provision except as expressly provided in this Agreement,
                and any
                conditions, warranties or other terms implied by statute or common
                law are
                excluded from this Agreement to the fullest extent permitted by
                law.

            

    

    

    
      	10.3.2	
              Without
                limiting the scope of Clause 10.3.1, CIMYM does not give any warranty,
                representation or undertaking:-

            

    

    

    
      	
            	(a)	
              as
                to the efficacy or usefulness of any of the Licensed Intellectual
                Property; or

            

    

    

    
      	
            	(b)	
              that
                any of the Licensed Patent Rights is or will be valid or subsisting
                or (in
                the case of an application) will proceed to grant;
                or

            

    

    

    
      	
            	(c)	
              that
                the use of any of the Licensed Intellectual Property, the manufacture,
                sale or use of the Licensed Product or the exercise of any of the
                rights
                granted under this Agreement will not infringe any other intellectual
                property or other rights of any other person;
                or

            

    

    

    
      	
            	(d)	
              that
                the Licensed Know-how or any other information or materials communicated
                or provided by CIMYM to Oncoscience under or in connection with this
                Agreement will produce Licensed Product of satisfactory quality or
                fit for
                the purpose for which Oncoscience intended;
                or

            

    

    

    
      	
            	(e)	
              as
                imposing any obligation on CIMYM to bring or prosecute actions or
                proceedings against third parties for infringement or to defend any
                action
                or proceedings for revocation of any of the Licensed Patent Rights;
                or

            

    

    

    
      	
            	(f)	
              as
                imposing any liability on CIMYM in the event that any third party
                supplies
                Licensed Product to customers located in the
                Territory.

            

    

    

    
      	10.4	
              Indemnity
                and insurance.
                Oncoscience shall indemnify and hold harmless CIMYM and (except as
                otherwise provided in any Supply Agreement) CIMAB and their respective
                Affiliates and their respective officers, employees, consultants,
                agents
                and representatives (the “Indemnitees”) against all third party Claims
                which may be asserted against or suffered by any of the Indemnitees
                and
                which relate to:

            

    

    

    
      	
            	(a)	
              the
                use of any Delivered Items; or

            

    

    

    
      	
            	(b)	
              the
                manufacture, distribution, sale, supply or use of the Licensed Product
                or
                any other products or services which incorporate any Delivered
                Items,

            

    

    

    by
      or on
      behalf of Oncoscience, its Affiliates or sub-licensees, or subsequently by
      any
      third party, including without limitation claims based on product liability
      laws. For the duration of this Agreement, Oncoscience shall, or shall ensure
      that its sub-licensee shall, maintain clinical trials and product liability
      insurance with a reputable insurer in an amount not less than the minimum amount
      required by law or best industry practice in each country of the Territory
      (or,
      in any country, if no such law or practice exists in that country, in an amount
      of at least UK£5,000,000
      (five
      million pounds sterling) per claim or series of claims).

    
      
        
        

      

      
        22

        
          

        

      

      
        
        

      

    

    

    
      	10.5	
              Liability.
                Subject to Clause 10.4, but notwithstanding any other provision of
                this
                Agreement, no Party shall be liable to any other Party to this Agreement
                in contract, tort, negligence, breach of statutory duty or otherwise
                for
                any loss, damage, costs or expenses of any nature whatsoever incurred
                or
                suffered by that other party or its Affiliates of an indirect or
                consequential nature including without limitation any economic loss
                or
                other loss of turnover, profits, business or
                goodwill.

            

    

    

    
      	11.	
              Duration
                and Termination

            

    

    

    
      	11.1	
              Commencement
                and Termination by Expiry.
                This Agreement, and the licences granted hereunder, shall come into
                effect
                on the Commencement Date and, unless terminated earlier in accordance
                with
                this Clause 11, shall continue in force on a country by country basis
                in
                the Territory until the latest of:

            

    

    

    
      	
            	(a)	
              The
                date on which all the Licensed Patents have expired or been revoked
                in
                that country without a right of further appeal,
                and

            

    

    

    
      	
            	(b)	
              The
                date on which any Orphan Drug Status for Licensed Product in that
                country
                has expired; and

            

    

    

    
      	
            	(c)	
              The
                tenth anniversary of the date of the first commercial sale of Licensed
                Product in that country by Oncoscience, its Affiliate or sub-licensee
                or,
                if that country is part of the European Union, the tenth anniversary
                of
                the date of the first commercial sale of the Licensed Product in
                the
                European Union by Oncoscience, its Affiliate or
                sub-licensee;

            

    

    

    and
      on
      such date this Agreement and the licences granted hereunder shall terminate
      automatically
      by expiry.

    

    
      	11.2	
              Early
                termination

            

    

    

    
      	11.2.1	
              Oncoscience
                may terminate this Agreement at any time on 90 days notice in writing
                to
                CIMYM.

            

    

    

    
      	11.2.2	
              Without
                prejudice to any other right or remedy, either of CIMYM or Oncoscience
                may
                terminate this Agreement at any time by notice in writing to the
                other of
                them (“Other Party”), such notice to take effect as specified in the
                notice:

            

    

    

    
      	
            	(a)	
              if
                the Other Party (which in the case of Oncoscience shall include any
                Affiliate or sub-licensee of Oncoscience) is in material breach of
                this
                Agreement and, in the case of a breach capable of remedy within 90
                days,
                the breach is not remedied within 90 days of the Other Party receiving
                notice specifying the breach and requiring its remedy;
                or

            

    

    

    
      	
            	(b)	
              if
                the Other Party (which in the case of Oncoscience shall include any
                Affiliate or sub-licensee of Oncoscience) becomes insolvent, or if
                an
                order is made or a resolution is passed for the winding up of the
                Other
                Party (other than voluntarily for the purpose of solvent amalgamation
                or
                reconstruction), or if an administrator, administrative receiver
                or
                receiver is appointed in respect of the whole or any part of the
                Other
                Party’s assets or business, or if the Other Party makes any composition
                with its creditors or takes or suffers any similar or analogous action
                in
                consequence of debt; or

            

    

    
      
        
        

      

      
        23

        
          

        

      

      
        
        

      

    

    

    
      	
            	(e)	
              if
                the first Phase II clinical trial for the Licensed Product in the
                Field in
                the Territory has not commenced within a period of two years after
                the
                Commencement Date; or

            

    

     

    
      	
            	(d)	
              if
                the first Regulatory Approval for marketing the Licensed Product
                in the
                Field in the Territory is not obtained within a period of five years
                after
                the Commencement Date.

            

    

    

    
      	11.2.3	
              CIMYM
                may forthwith terminate this Agreement by giving written notice to
                Oncoscience if Oncoscience or its Affiliate or sub-licensee commences
                legal proceedings, or assists any third party to commence legal
                proceedings, to challenge the validity of any of the
                Patents.

            

    

    

    
      	11.2.4	
              The
                Parties acknowledge and agree that Oncoscience’s remedy for any breach by
                CIMAB of its obligations under Clause 5 shall be as set out in Clause
                5.4
                or in any Supply Agreement that CIMAB and Oncoscience may execute
                pursuant
                to Clause 5.5. Accordingly, breach of Clause 5 shall not entitle
                any Party
                to terminate this Agreement.

            

    

    

    
      	11.3	
              Consequences
                of termination

            

    

    

    
      	11.3.1	
              Upon
                termination of this Agreement for any reason otherwise than in accordance
                with Clause 11.1:

            

    

    

    
      	
            	(a)	
              If
                termination occurs afler the first commercial sale of Licensed Product,
                Oncoscience and its sub-licensees shall be entitled to sell, use
                or
                otherwise dispose of (subject to payment of royalties under Clause
                7.1 or
                7.2) any unsold or unused stocks of the Licensed Product for a period
                of 6
                months following the date of termination; and if termination occurs
                prior
                to the first commercial sale of Licensed Product, Oncoscience shall
                forthwith return all such stocks of Licensed Product and Licensed
                Know-how
                to CIMYM free of charge;

            

    

    

    
      	
            	(b)	
              subject
                to paragraph (a) above, Oncoscience shall no longer be licensed to
                use or
                otherwise exploit in any way, either directly or indirectly, any
                of the
                Licensed Intellectual Property;

            

    

    

    
      	
            	(c)	
              subject
                to paragraph (a) above, Oncoscience shall consent to the cancellation
                of
                any formal licence granted to it, or of any registration of it in
                any
                register, in relation to any of the Licensed Patent
                Rights;

            

    

    

    
      	
            	(d)	
              the
                provisions of the following clauses shall continue in force without
                limit
                of time, except that the continuing obligations under Clause 4, referred
                to in paragraph (i) below, shall survive for a period of 5 years
                from the
                termination of this Agreement:

            

    

    

    
      	
            	(i)	
              Clauses
                4.3 (except that Oncoscience shall not have any continuing right
                to
                use
                Licensed Know-how or any other information received from CIMYM or
                CIMAB),
                4.4(a) (subject to Clause 4.5) (and no further disclosure may be
                made by
                Oncoscience under Clause 4.7);

            

    

    
      
        
        

      

      
        24

        
          

        

      

      
        
        

      

    

    

    
      	
            	(ii)	
              Clause
                7 (in respect of sales of Licensed Product made prior to termination,
                or
                after termination under the first part of Clause 11.3.1(a));
                and

            

    

    

    
      	
            	(iii)	
              Clause
                10.3 and 12; and

            

    

    

    
      	
            	(e)	
              subject
                as provided in this Clause 11.3.1 and 11.3.2, and except in respect
                of any
                accrued rights, neither Party shall be under any further obligation
                to the
                other.

            

    

    

    
      	11.3.2	
              Upon
                termination of this Agreement for any reason otherwise than in accordance
                with Clause 11.1 and at CIMYM’s request, Oncoscience shall, without charge
                to, or other obligation on the part of,
                CIMYM:

            

    

    

    
      	
            	(a)	
              transfer
                to CIMYM exclusively all clinical and other data relating to the
                development of Licensed Product;

            

    

    

    
      	
            	(b)	
              to
                the extent possible, seek to have any Regulatory Approvals (including
                without limitation product licences and pricing approvals) and other
                permits and applications transferred into the name of CIMYM or its
                nominee;

            

    

    

    
      	
            	(c)	
              grant
                CIMYM an exclusive, worldwide licence, with the rights to grant
                sub-licences, under all Arising Intellectual Property and any improvements
                and other intellectual property owned or controlled by Oncoscience
                relating to Licensed Product; and

            

    

    

    
      	
            	(d)	
              grant
                CIMYM or its nominee the right to continue to use any product name
                that
                had been applied to the Licensed Product prior to termination of
                this
                Agreement.

            

    

    

    
      	12.	
              General

            

    

    

    
      	12.1	
              Force
                majeure.
                Neither Party shall have any liability or be deemed to be in breach
                of
                this Agreement for any delays or failures in performance of this
                Agreement
                which result from circumstances beyond the reasonable control of
                that
                Party, including without limitation labour disputes involving that
                Party.
                The Party affected by such circumstances shall promptly notify the
                other
                Party in writing when such circumstances cause a delay or failure
                in
                performance and when they cease to do
                so.

            

    

    

    
      	12.2	
              Language
                and Amendment.
                This Agreement is made in the English language and may only be amended
                in
                the English language in writing signed by duly authorised representatives
                of the Parties. In the event of any conflict in meaning between the
                English language version and any translation of this Agreement, the
                English language version shall
                prevail.

            

    

    

    
      	12.3	
              Assignment
                and third party rights.

            

    

    

    
      	12.3.1	
              Subject
                to Clause 12.3.2 below, no Party shall assign, mortgage, charge,
                or
                otherwise transfer any rights or obligations under this Agreement,
                nor any
                of the Patents or rights under the Patents, without the prior written
                consent of the Parties.

            

    

    
      
        
        

      

      
        25

        
          

        

      

      
        
        

      

    

    
      	12.3.2	
              With
                the prior written consent of the other Parties, a Party may assign
                all its
                rights and obligations under this Agreement together with its rights
                in
                the Patents to any company to which it transfers all or substantially
                all
                of its assets or business in the Field, provided that the assignee
                undertakes to the other Party to be bound by and perform the obligations
                of the assignor under this
                Agreement.

            

    

    

    
      	12.4	
              Waiver.
                No failure or delay on the part of either Party to exercise any right
                or
                remedy under this Agreement shall be construed or operate as a waiver
                thereof, nor shall any single or partial exercise of any right or
                remedy
                preclude the further exercise of such right or
                remedy.

            

    

    

    
      
        	12.5	
                Invalid
                  clauses.
                  If any provision or part of this Agreement is held to be invalid,
                  amendments to this Agreement may be made by the addition or deletion
                  of
                  wording as appropriate to remove the invalid part or provision
                  but other
                  wise retain the provision and the other provisions of this Agreement
                  to
                  the maximum extent permissible under applicable
                  law.

              

      

    

    

    
      	12.6	
              No
                Agency.
                Neither Party shall act or describe itself as the agent of the other,
                nor
                shall it make or represent that it has authority to make any commitments
                on the other’s behalf.

            

    

    

    
      	12.7	
              Interpretation.
                In this Agreement:

            

    

    

    
      	
            	(a)	
              the
                headings are used for convenience only and shall not affect its
                interpretation;

            

    

    

    
      	
            	(b)	
              references
                to persons shall include incorporated and unincorporated persons;
                references to the singular include the plural and vice versa; and
                references to the masculine include the
                feminine;

            

    

    

    
      	
            	(c)	
              references
                to Clauses and Schedules mean clauses of, and schedules to, this
                Agreement;

            

    

    

    
      	
            	(d)	
              references
                to any Party shall include their permitted successors and permitted
                assignees;

            

    

    

    
      	
            	(e)	
              references
                to any licence shall mean, where the context requires, a
                sub-licence;

            

    

    

    
      	
            	(f)	
              where
                the word “including” is used, it shall be understood as meaning “including
                without limitation”; and

            

    

    

    
      	
            	(g)	
              references
                to the grant of “exclusive” rights shall mean that the person granting the
                rights shall neither grant the same rights (in the same Field and
                Territory and in respect of the same Licensed Product) to any other
                person, nor exercise those rights directly to the extent that and
                for as
                long as the Licensed Product is within Valid Claims of unexpired
                Licensed
                Patent Rights or, to the extent that the Licensed Product is protected
                by
                Licensed Know-how that have not become known and available to the
                public,
                for a period of 10 years from the first commercial sale of Licensed
                Product in any part of the
                Territory.

            

    

    

    
      	12.8	
              Notices

            

    

    

    
      	12.8.1	
              Any
                notice to be given under this Agreement shall be in writing and shall
                be
                sent by first class mail, air mail or by courier, or by fax (confirmed
                by
                first class mail or air mail) to the address of the relevant Party
                set out
                at the head of this Agreement, or to the relevant fax number set
                out
                below, or such other address or fax number as that Party may from
                time to
                time notify to the other Party in accordance with this Clause 12.8.
                The
                fax numbers of the Parties are as
                follows:

            

    

    
      
        
        

      

      
        26

        
          

        

      

      
        
        

      

    

     

    
      	
              Party
                

            	 	
              Fax
                number

            	 
	 	 	 	 
	
              CIMYM
                

            	 	001
              905 629 4959	 
	
              CIMAB
                

            	 	0053
              7273 3509	 
	
              Oncoscience
                

            	 	0049
              4103 1808 820	 

    

    

    
      	12.8.2	
              Notices
                sent as above shall be deemed to have been received three working
                days
                after the day of posting (in the case of inland first class mail
                or
                national courier), or seven working days after the date of posting
                (in the
                case of air mail or international courier), or on the next working
                day
                after transmission (in the case of fax messages, but only if a
                transmission report is generated by the sender’s fax machine recording a
                message from the recipient’s fax machine, confirming that the fax was sent
                to the number indicated above and confirming that all pages were
                successfully transmitted).

            

    

    

    
      	12.9	
              Law
                and Jurisdiction. The validity, construction and performance of this
                Agreement shall be governed by English law. Any dispute arising out
                of or
                in connection with this Agreement, including any question regarding
                its
                existence, validity or termination, shall be referred to and finally
                resolved by arbitration by a single arbitrator in London under the
                Rules
                of the London Court of International Arbitration (the “Rules”), which
                Rules are deemed to be incorporated by reference into this clause.
                The
                language to be used in the arbitral proceedings shall be English.
                The
                arbitrator shall be chosen by the Parties or, failing agreement as
                to the
                choice of arbitrator within 28 days of one Party requesting that
                an
                arbitrator by chosen, appointed in accordance with the Rules. However,
                nothing in this Agreement shall prevent a Party from seeking an interim
                injunction in any court of competent
                jurisdiction.

            

    

    

    
      	12.10	
              Further
                action. Each Party agrees to execute, acknowledge and deliver such
                further instruments, and do all further similar acts, as may be necessary
                or appropriate to carry out the purposes and intent of this
                Agreement.

            

    

    

    
      	12.11	
              Announcements.
                Neither Party shall make any press or other public announcement concerning
                any aspect of this Agreement, or make any use of the name of the
                other
                Party in connection with or in consequence of this Agreement, without
                the
                prior written consent of the other Party, except as may be required
                by law
                or by the rules of any stock exchange on which either Party is listed.
                The
                Parties shall agree a form of press release for issue on signature
                of this
                Agreement.

            

    

    

    
      	12.12	
              Entire
                agreement. This Agreement, including its Schedules, sets out the
                entire agreement between the Parties relating to its subject matter
                and
                supersedes all prior oral or written agreements, arrangements or
                understandings between them relating to such subject matter. The
                Parties
                acknowledge that they are not relying on any representation, agreement,
                term or condition that is not set out in this Agreement. Nothing
                in this
                Agreement excludes liability for
                fraud.

            

    

    

    
      	12.13	
              Third
                party rights. Each of the persons identified as Indemnitees in Clause
                10.4 may in his own right enforce the provisions of those respective
                Clauses. Except as provided in the previous sentence of this Clause
                12.12,
                this Agreement is not made for the benefit of, nor shall any of its
                provisions be enforceable by, any person other than the parties to
                this
                Agreement and their respective successors and permitted
                assignees.

            

    

    
      
        
        

      

      
        27

        
          

        

      

      
        
        

      

    

    
      	12.14	
              Non-compete.
                Oncoscience warrants, represents, acknowledges and agrees, in respect
                of
                it and its Affiliates that:

            

    

    

    
      	
            	(a)	
              they
                do not have any interest in any technology that competes with the
                Licensed
                Intellectual Property, nor is any of them engaged in any research
                or
                development activities with respect to any product that would compete
                with
                the Licensed Products; and

            

    

    

    
      	
            	(b)	
              for
                as long as this Agreement remains in force, they will not enter into
                any
                agreement with any Person other than CIMAB or CIMYM for the development
                or
                marketing of any product that is, or contains, (i) any other
                anti-EGF-receptor inhibitor, (ii) any product or component or sequence
                of
                EGF-R, EGF-R ligands, or any small tyrosine kinase
                inhibitor.

            

    

    

    
      	12.15	
              Amendment
                and Restatement. The Original Agreement is hereby terminated. This
                Agreement supersedes, and amends and restates the Original
                Agreement.

            

    

    
      
        
        

      

      
        28

        
          

        

      

      
        
        

      

    

    Agreed
      by the
      Parties through their authorised signatories:

    

    For
      and
      on behalf of CIMYM,
      Inc.

    

    
      	
              [ILLEGIBLE]  
                

            	 	  

	
              signed

            	 	
              signed

            
	 	 	 
	
              [ILLEGIBLE]

            	 	  

	
              print
                name

            	 	
              print
                name

            
	 	 	 
	Chair
              & CEO	 	  

	
              title

            	 	
              title

            
	 	 	 
	Aug
              27/2007	 	  

	
              date

            	 	
              date

            

    

    

    For
      and
      on behalf of CIMAB
      S.A.

    

    
      	
              [ILLEGIBLE]

            	 	  

	
              signed

            	 	
              signed

            
	 	 	 
	
              [ILLEGIBLE]

            	 	  

	
              print
                name

            	 	
              print
                name

            
	 	 	 
	General
              Manager	 	  

	
              title

            	 	
              title

            
	 	 	 
	14/09/2007	 	  

	
              date

            	 	
              date

            
	 	 	 
		 	 

    

    

    For
      and
      on behalf of Oncoscience
      AG

    

    
      	/s/
              F. Bach 	 	   

	
              signed

            	 	
              signed

            
	 	 	 
	F.
              BACH	 	   

	
              print
                name

            	 	
              print
                name

            
	 	 	 
	CEO	 	   

	
              title

            	 	
              title

            
	 	 	 
	
              [ILLEGIBLE]

            	 	   

	
              date

            	 	
              date

            
	 	 	 
		 	 

    

     

    
      
        
        

      

      
        29

        
          

        

      

      
        
        

      

    

    Schedule
      1

    

    Licensed
      Patent Rights

    

    The
      patents and patent applications listed in this Schedule are, or may become,
      relevant to this Agreement, but they also contain other rights not licensed
      under this Agreement. Thus their inclusion here is limited to the extent if
      any
      that they would protect the exploitation of Licensed Product for use within
      the
      Field.

    

    Monoclonal Antibodies
      Recognizing the Epidermal Growth Factor Receptor, Cells and Methods for Their
      Production and Compositions Containing Them (mR3)

    

      
        	
                Country

              	 	
                Filing
                  

                Date

              	 	
                Serial
                  No.

              	 	
                PubIn
                  

                Date

              	 	
                Publn
                  

                No.

              	 	
                Issue
                  

                Date

              	 	
                Patent
                  

                No.

              
	
                Europe1

              	 	
                18 Aug 93

              	 	
                93202428.4

              	 	
                09 Mar 94

              	 	
                586002

              	 	
                Granted

              	 	
                586002

              

      

    

    

    [territories
      of grant within Europe to be confirmed by CIMYM to Oncoscience]

    

    Humanized
      and Chimeric Antibodies for EGF Receptor Used in Diagnosis and Therapy of
      Tumours (hR3)

    

      
        	
                Country

              	 	
                Filing
                  

                Date2

              	 	
                Serial
                  No.

              	 	
                Publn
                  

                Date

              	 	
                Publn
                  

                No.

              	 	
                Issue
                  

                Date

              	 	
                Patent
                  

                No.

              
	
                Europe*

              	 	
                15 Nov 95

              	 	
                95203126.8

              	 	
                22 May 96

              	 	
                712,863

              	 	
                Granted

              	 	
                712,863

              

      

    

    

    *
      Validated in Austria, Belgium, Switzerland, Liechtenstein, Germany, Spain,
      France, United Kingdom, Italy, Ireland

     

    
      
        

      

    

    1
      Priority of 18 Aug 92 based on CU 100/92, and 01 Mar 93 based on
      CU 17/93

    2
      Priority of 18 Nov 94 based on CU 128/94

    
      
        
        

      

      
        30

        
          

        

      

      
        
        

      

    

    Schedule
      2

    Licensed
      Know-how

    

    All
      documentation that has been submitted by YM Biosciences, Inc. to the Health
      Protection and Food Branch of the Department of Health and Welfare of Canada
      in
      connection with an application for an IND for the Licensed Product in Canada,
      together with clinical trial data generated by CIMAB.

    
      
        
        

      

      
        31

        
          

        

      

      
        
        

      

    

    Schedule
      3

    Initial
      Development and Commercialisation Plan

    

    Part
      A:
      Initial Development Programme

    

    The
      development programme will include:

    

    
      	
            	1.	
              A
                registration study in glioma. It is provisionally estimated that
                enrolment
                will be in the range of 80 – 100
                patients.

            

    

    

    
      	
            	2.	
              A
                pilot study in paediatric brain tumours. It is provisionally estimated
                that enrolment will be in the range of 6 – 10
                patients.

            

    

    

    
      	
            	3.	
              A
                registration study in paediatric brain tumours. It is provisionally
                estimated that enrolment will be in the range of 60 – 80
                patients.

            

    

    

    
      	
            	4.	
              A
                pilot study in metastatic pancreatic cancer. It is provisionally
                estimated
                that enrolment will be in the range of 14 – 20
                patients.

            

    

    

    
      	
            	5.	
              Application
                for Orphan Drug Status for the Product with the
                EMEA.

            

    

    

    Subject
      to availability of clinical trial materials, regulatory approvals and ethical
      votum, it is anticipated that recruitment for the above studies will
      commence as follows:

     

    Item
      2
      will commence on January 15, 2004. Items 1, 3 and 4 above will commence on
      April
      1, 2004.

    

    The
      date
      for submission of item 5 will be assessed based on the receipt by Oncoscience
      of
      the documentation that has been submitted to the Health Protection and Food
      Branch of the Canadian Department of Health and Welfare

    
      
        
        

      

      
        32

        
          

        

      

      
        
        

      

    

    Schedule
      4

    Appointment
      of expert

    

    1.
      Pursuant to Clause 8.3, CIMYM may serve notice on Oncoscience (“Referral
      Notice”) that it wishes to refer to an expert (the “Expert”) the questions set
      out in Clause 8.2.

    

    2.
      CIMYM
      and Oncoscience (in this Schedule, the “parties”) shall agree the identity of a
      single independent, impartial Expert to determine such questions. In the absence
      of such agreement within 30 days of the Referral Notice, each party shall
      appoint its own expert adviser, and the two appointed expert advisers shall
      together appoint an independent, impartial Expert and such Expert shall alone
      resolve the questions referred to in paragraphs 1 and 2 above.

    

    3.
      60
      days after the giving of a Referral Notice, both parties shall exchange
      simultaneously statements of case in no more than 10,000 words, in total, and
      each side shall simultaneously send a copy of its statement of case to the
      Expert.

    

    4.
      Each
      party may, within 30 days of the date of exchange of statement of case pursuant
      to paragraph 3 above, serve a reply to the other side’s statement of case of not
      more than 10,000 words. A copy of any such reply shall be simultaneously sent
      to
      the Expert.

    

    5.
      The
      Expert shall make his or her decision on the said questions on the basis of
      written statements and supporting documentation only and there shall be no
      oral
      hearing. The Expert shall issue his or her decision in writing within 30 days
      of
      the date of service of the last reply pursuant to paragraph 4 above or, in
      the
      absence of receipt of any replies, within 60 days of the date of exchange
      pursuant to paragraph 3 above.

    

    6.
      The
      Expert’s decision shall be final and binding on the parties.

    

    7.
      The
      Expert’s charges shall be borne by the parties in such proportions as the Expert
      shall decide.

    

    8.
      All
      documents referred to in this schedule shall be in the English
      language.

    
      
        
        

      

      
        33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]